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ABSTRACT  
   
Calcitonin Gene-Related Peptide (CGRP) is an intrinsically disordered protein 
that has no regular secondary structure, but plays an important role in vasodilation and 
pain transmission in migraine. Little is known about the structure and dynamics of the 
monomeric state of CGRP or how CGRP is able to function in the cell, despite the lack of 
regular secondary structure. This work focuses characterizing the non-local structural and 
dynamical properties of the CGRP monomer in solution, and understanding how these 
are affected by the sequence and the solution environment. The unbound, free state of 
CGRP is measured using a nanosecond laser-pump spectrophotometer, which allows 
measuring the end-to-end distance (a non-local structural property) and the rate of end-to-
end contact formation (intra-chain diffusional dynamics). The data presented in this work 
show that electrostatic interactions strongly modulate the structure of CGRP, and that 
peptide-solvent interactions are sequence and charge dependent and can have a 
significant effect on the internal dynamics of the peptide. In the last few years migraine 
research has shifted focus to disrupting the CGRP-receptor pathway through the design of 
pharmacological drugs that bind to either CGRP or its receptor, inhibiting receptor 
activation and therefore preventing or reducing the frequency of migraine attacks. 
Understanding what types of intra- and inter-chain interactions dominate in CGRP can 
help better design drugs that disrupt the binding of CGRP to its receptor. 
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CHAPTER 1 
INTRINSICALLY DISORDERED PROTEINS 
 
1.1. INTRODUCTION TO INTRINSICALLY DISORDERED PROTEINS 
 
The focus of this work is on elucidating the structure and dynamics of calcitonin gene-
related peptide, or CGRP. CGRP has very little secondary structure in solution1-3 and is 
part of a class of proteins that are intrinsically disordered, referred to as IDPs. Unlike 
enzymes that have a regular secondary structure and bind to specific binding partners, 
IDPs have no regular three dimensional structure and can be more promiscuous, with 
multiple binding partners.4-7 However, despite this lack of regular structure, IDPs are still 
able perform biological functions in the cell. About one third to one half of all eukaryotic 
proteins have extensive disordered regions,7-8 suggesting an evolutionary advantage for 
protein disorder. The exact mechanism for how the structure and dynamics of the 
unbound state of disordered proteins increase receptor promiscuity and affect the binding 
rates is unclear. It has been proposed that the presence of disordered states helps increase 
protein efficacy.9 Some studies suggest that IDPs operate a fly-casting mechanism where 
the intrinsic disorder of IDPs allow them to bind weakly to their partners from long 
distances, thereby increasing the on-rate of binding.10 However, other studies show that 
for at least some IDPs, the rate of binding is not diffusion limited and the on-rate of 
binding depends on the structure of the monomer.11 As IDPs perform signaling and 
regulatory functions in the cell, it is important to elucidate the structure and dynamics of 
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IDPs to understand how IDPs bind to their partners and perform biological functions in 
the cell.  
 
1.2. WHAT DETERMINES THE STRUCTURE OF IDPS 
 
Interestingly, research has shown that despite the fact that IDPs have no regular three 
dimensional structure, IDPs can occupy a range of “structures” ranging from extended 
coils with little structure to collapsed states with extensive secondary structure, as shown 
in Figure 1.1 below.12 This suggests that while IDPs have no characteristic three 
dimensional “structure,” there are long range interactions present which occur on the 
same length scale of the protein that affect the structure and dynamics, and therefore the 
thermodynamics and kinetics of binding, in IDPs.  
 
 
 
Figure 1.1.  Representative structures of IDPs. The structure of IDPs can 
range from extended coils with no secondary structure to native molten 
globules with extensive secondary structure (Uversky, Protein J 2009).12 
 
  3 
Despite the fact that IDPs occupy a wide variety of structures, they are still more 
expanded than natively folded proteins (NFPs). Marsh and Forman-Kay analyzed small-
angle x-ray scattering (SAXS) and dynamic light scattering (DLS) data from folded 
proteins, chemically denatured proteins, and disordered proteins and found that although 
disordered proteins are more expanded than NFPs in aqueous solvent, they are more 
compact than unfolded proteins in denaturant (Figure 1.2).13 This suggests the presence 
of attractive intra-chain interactions in IDPs in aqueous solvent, despite the lack of 
regular three dimensional structure.14  
 
 
Figure 1.2. Compaction of IDPs in water. Plot of hydrodynamic radius Rh 
as a function of the number of residues for a selected sample of folded 
proteins (filled squares), unfolded proteins (filled circles) and IDPs (open 
diamonds). Despite being disordered, IDPs have a smaller Rh than 
unfolded proteins (Marsh and Forman-Kay Biophysical J, 2010). 
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To understand how IDPs can have attractive intra-chain interactions yet still be 
disordered, Uversky, et al plotted the net charge versus the average side chain 
hydrophobicity of various IDPs and NFPs, and found that on average IDPs have a higher 
net charge and lower net hydrophobicity than NFPs (Figure 1.3).15  
 
 
Figure 1.3. Uversky Plot. Plot of the mean net charge versus 
hydrophobicity of a selection of intrinsically disordered (open circles) and 
folded proteins (grey squares). (Uversky Proteins, 2000). 
 
This is intuitive in that charge repulsion will create expanded states, especially if there 
are few hydrophobic residues to promote collapsed, folded states. However, this is only a 
generalization and most IDPs, with few exceptions, are not that significantly different in 
net charge or hydrophobicity than NFPs, but still remain disordered. Other studies have 
shown that IDPs have slightly different sequence composition, with IDPs having a higher 
IDPs 
NFPs 
  5 
composition of “low-complexity” or “disorder promoting” amino acids such as prolines 
compared to folded proteins.13,16 Further analysis of the sequence of various IDPs found 
that the amount of compaction seen in IDPs does not seem to correlate with secondary 
structure content, but instead on their net charge and amino acid content.13 
 
Therefore it is an open question in the field as to what causes IDPs to adopt expanded, 
disordered conformations but still have long range attractive intra-chain interactions that 
cause IDPs to be more collapsed than unfolded proteins. As IDPs generally have a higher 
net charge than natively folded proteins,15 electrostatic interactions appear to be an 
important factor in the structural propensities of IDPs. It is well known from polymer 
theories that chain stiffness can depend on Coulomb repulsion and the fraction of positive 
and negative charges (including how they are spaced along the linear sequence).17-19 It 
has been suggested that the polymeric properties of IDPs can be explained by such 
models,20-22 with variations in the environmental pH and the presence of ions in the extra-
cellular region where CGRP (and other IDPs) are secreted playing an important role in 
their structure and dynamics.  
 
As excluded volume interactions are the most basic interactions that give rise to the 
polymeric properties of IDPs, steric interactions might play a role in the expansion of 
IDPs in water. Even in small non-proline, non-hydrophobic side chain peptides, it was 
seen that restrictions in phi-psi angle extend beyond nearest neighbors, disproving the 
isolated-pair hypothesis and suggesting that steric clashes can have a significant effect on 
the structure of proteins.23 IDPs also tend to have a higher proportion of diso
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promoting residues such as prolines which might play an important role in the structure 
of IDPs. Similar to the simulations of steric clashes, simulations have also showed that 
the presence of prolines can cause expansion in short peptides (but the effect is smaller in 
longer proteins).24  
 
Other models suggest that it is not side chain-side chain interactions, but rather backbone-
backbone interactions that cause compaction in disordered proteins. Measurements of the 
intra-chain diffusion times in polyglycine, a protein with no residues, and other peptides 
of varying hydrophobicity all saw faster diffusion than expected, suggesting that it is 
backbone interactions that drive collapse.25 Modeling of polyglutamine (polyQ) which 
lacks hydrophobic residues showed that PolyQ populates collapsed states, further 
evidence of backbone-backbone interactions modulating the structure of disordered 
proteins.26  
 
There are currently many models attempting to explain why, despite being disordered, 
IDPs are more compact than unfolded proteins, with the amount of compaction being 
sequence dependent. However, due to fast reconfiguration times, there is relatively few 
experimental data to verify these models and help understand the conformations IDPs 
adopt. As we will see in the next section, the study and characterization of long range 
interactions are important to discover how IDPs function in the cell. 
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1.3. HOW THE STRUCTURE AND INTERNAL DYNAMICS OF IDPS AFFECT 
THEIR BIOLOGICAL FUNCTION 
 
The disordered structure of IDPs has been proposed to play an important role in 
biological function through a number of mechanisms. It has been suggested that intrinsic 
disorder increases receptor promiscuity, with one protein recorded as having over 80 
binding partners.7 Disorder also appears to play a role in binding kinetics with the rate of 
association “enhanced” by disorder, including a proposed fly-casting mechanism where 
IDPs weakly bind to their partners from long distances and then adopt the folded, 
functional conformations, thereby increasing the on-rate of binding.10 Other experiments 
have shown that the kinetics of binding is not diffusion limited, suggesting that at least 
some IDPs might not bind through induced fit.11 In fact, experiments have shown that 
IDPs, while unstructured, are still more compact than unfolded proteins, indicating the 
presence of attractive intra-chain interactions in water13 and suggests that IDPs have the 
ability to favorably bind to its receptors through attractive inter-chain interactions.  
 
Other theories focus on the role that the dynamics of conformational sampling plays in 
the function of IDPs. Some focus on how electrostatic interactions might drive binding 
thermodynamics and kinetics. For example, fast reconfiguration of a charged IDP will 
create an average electric field that favorably interacts with a charged receptor site.27 
Modeling shows that inter-residue contacts formed due to electrostatics can determine the 
polymeric properties of proteins, and might provide a mechanism for receptor 
specificity.17 Some experiments have shown that some IDPs have large electrostatic 
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energies, which suggests that electrostatic interactions with the receptor might play a 
significant role in the binding affinity and receptor specificity of IDPs.22 Other models 
suggest that internal friction is important in IDPs, slowing down dynamics in solution and 
affecting the binding rate.  Prolines slow down the dynamics of short peptides but not 
longer ones24 while more expanded proteins have lower internal friction and therefore 
faster dynamics28 with faster chain dynamics tending to correlate with high internal 
friction.29 Other studies show that chain dynamics can speed up upon binding30: this is 
called the induced fit mechanism where the IDP folds upon binding, with non-native 
interactions with binding partners increasing the binding rate.4  
 
There are many proposed mechanisms to explain how the structure and dynamics of 
disordered proteins allow these proteins to carry out their biological function despite the 
lack of regular three dimensional structure. However, there is limited experimental 
information to support these proposed mechanisms due to fast reconfiguration on short 
timescales making the measurement of these global properties difficult. As it appears that 
the structure and dynamics of IDPs are important to the thermodynamics and kinetics of 
binding,9,10 to understand how disordered proteins function in the cell experimental 
measurements of these non-local properties are needed. The goal of this work is to study 
the fundamental aspects of CGRP that are relevant to the biology of CGRP, including 
drug and receptor binding and activation. 
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CHAPTER 2 
CGRP AND THE CALCITONIN PEPTIDE FAMILY 
 
2.1 CALCITONIN GENE-RELATED PEPTIDE 
 
2.1.1 THE BIOLOGICAL FUNCTION OF CALCITONIN GENE-RELATED PEPTIDE 
 
The focus of this work is on the structure and dynamics of CGRP, a short 37-residue 
intrinsically disordered hormone peptide that is primarily produced in both central and 
peripheral neurons.1,2 CGRP is present in the cardiovascular, nervous and gastrointestinal 
systems, and has been strongly implicated in migraine pathophysiology. CGRP is one of 
the most potent vasodilators in the body and is involved in the transmission of pain 
signals.1-5   
 
In the last few years, there has been a significant focus on CGRP and its role in migraine 
headache. In migraine, one of the primary signs of an attack is increased concentrations 
of CGRP in the brain, with a migraine attack corresponding to the release of CGRP from 
the trigeminal neurons in the brain, which densely enervate cerebral blood vessels.6-8 As 
Figure 2.1 shows, CGRP is released from trigeminal neurons into the extracellular space, 
where it then binds to CGRP receptors on the exterior of cebrebral vascular smooth 
muscles, causing vasodilation.9 Because of this and due to CGRP’s role as a potent 
vasodilator and in pain transmission, it is thought that CGRP plays a significant role in 
migraine. One of the current focuses of research on migraine is on inhibiting the binding 
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of CGRP to its receptor through receptor antagonists that bind to, but do not activate the 
receptor.7,8 It is thought that when CGRP binds and activates the CGRP receptors in the 
brain during migraine, in addition to increased blood flow that is a hallmark of migraine, 
elevated levels of CGRP can lead to pain signals, halos and other migraine 
symptoms.7,6,10   
 
 
 
Figure 2.1. CGRP and its receptors in migraine. CGRP is released from 
trigeminal neurons and binds to CGRP receptors located on vasculature or 
on mast cells, which cause vasodilation and inflammation respectively 
(Raddant & Russo, Expt. Rev. Mol. Med., 2011).9  
 
Clinical studies are focusing on monoclonal antibodies that bind to CGRP itself, thereby 
preventing activation of the receptor and either preventing migraine or reducing the 
severity of pain during migraine attacks.11-13 Other pharmacological studies are focusing 
on chemical and synthetic inhibitors that preferentially bind to CGRP receptors, with 
some currently in Phase II clinical trials.7,12-14  
  14 
As a potent vasodilator, CGRP not only has an important role in increased blood flow 
during migraine, but also regulates blood flow and vasoconstriction elsewhere in the 
body. CGRP is such a strong vasodilator that the application of pico- or femtomolar 
quantities of CGRP to the human skin is enough to cause reddening of the skin.3 In the 
circulatory system, CGRP plays an important role in reducing the effects of ischemia and 
myocardial infarction,15 where the local release of CGRP due to tissue acidosis is thought 
to provide a cardiac protective effect and promote healing.6,16,17 Other pathways in which 
CGRP’s vasodilatory effect plays a role includes Reynaud’s disease, where CGRP levels 
are lower than normal in the hands and feet, with vasoconstriction a major symptom of 
this disease; the intravenous application of CGRP causes vasodilation and promotes 
healing in Reynaud’s.18,19 CGRP plays a role in pulmonary vascular resistance by 
regulating vasoconstriction in the lungs, and a deficiency of CGRP in the lungs lead to an 
increase in pulmonary hypertension.5,20 Through its vasodilatory effect, CGRP also plays 
a role in the immune response of the body through an increase in blood flow to the 
affected area, allowing the immune system better access and thereby modulating 
inflammation.3,6,21  
 
Similarly, CGRP plays a role in the transmission of pain in the body. Studies in mice 
show that in inflamed areas of the body, the release of CGRP also plays a role in 
expression of pain.22,23 Metastatic cancer cells have been found to stimulate the 
production of CGRP producing neurons in the bone, suggesting that CGRP plays a role in 
bone pain in cancer patients.24 In addition, patients with lower back pain also have a 
measured increase in CGRP production near the affected areas of the vertebrae.25,26 In 
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migraine, clinical trials report that migraine sufferers experience a reduction in pain 
shortly after the administration of the pharmacological CGRP antagonists that inhibit the 
activation of the CGRP receptor.5,7,14  
 
All of this suggests that CGRP is a versatile neuropeptide that plays an important role in 
modulating many functions in the body through vasodilation, and is involved in the 
transmission of pain and migraine pathology. The current pharmacological focus on 
CGRP is on the interplay between CGRP and its receptor in order to design a better 
antagonist for migraine medication. As the release of CGRP has been associated with 
variations in extracellular conditions, such as tissue acidosis and high concentrations of 
ions, such environmental changes could potentially affect the structure and dynamics of 
CGRP. It is therefore important to study the structure and dynamics of the unbound state 
of CGRP, which can help understand how CGRP interacts with its receptor.  
 
2.1.2 THE STRUCTURE OF CALCITONIN GENE-RELATED PEPTIDE 
 
We present a brief review of the structural properties of the monomer state of CGRP, 
known prior to our current study. In the human body, CGRP has two variants which vary 
by only three amino acids, αCGRP and βCGRP, with αCGRP more widely studied.2,4 The 
focus of this work is on αCGRP only. 
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Figure 2.2. Sequence composition of CGRP. CGRP has 37 amino acids 
and is constrained by a disulfide bond between residues 2 and 7. The 
positively charged amino acids (red) and negatively charged amino acids 
(green) at pH 4.9 are highlighted.  
 
In its functional form, CGRP is amidated at the C terminus and contains a disulfide bond 
between the cysteines at residues 2 and 7, which confines residues 1-7 into a rigid 
structure.27-29 CGRP has a lower net charge and more hydrophobic residues compared to 
most IDPs, but is still highly disordered with very little regular secondary structure as 
evidenced by prior circular dichroism (CD) and nuclear magnetic resonance (NMR) 
studies on CGRP.   
 
 
Figure 2.3. Temperature dependence of CD spectra of CGRP. The CD 
spectra of CGRP was measured as a function of temperature- 4oC (□), 
15oC (◊), 30oC (x). (Manning, Biochem. and Biophy. Res. Com., 1989)31   
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CD studies, which report on the bulk secondary structure of peptides in solution, showed 
that in aqueous solution CGRP is primarily disordered with a small percentage (~20%) of 
apparent alpha helical content (Figure 2.3), which increases in the presence of 
trifluoroethanol (TFE), a helix-inducing solvent.30-31 As Figure 2.3 also shows, the 
apparent helical content of CGRP also exhibits a slight temperature dependence, 
decreasing with increasing temperature.31,32 According to 2D 1H NMR which reports on 
local contacts, the N-terminal disulfide loop of CGRP is followed by a stretch of residues 
from 8-18 with a somewhat higher propensity to sample helical states in solution, with 
the remaining residues 18-37 being highly disordered.27,28 In aqueous solution, 2D NMR 
of CGRP has been unable to resolve sequential NOEs, indicating a lack of well-defined 
three-dimensional structure.27 However, in helix stabilizing solutions, 2D NMR data 
reveal that residues 8-18 assume a well defined helical structure while residues thereafter 
remain largely disordered, with a few turn-type structures at the C-terminus.27,28,33 Due to 
the fast reconfiguration of CGRP, NMR has been unable to resolve secondary structure 
without the aid of helix stabilizing solvents. Moreover, there have been no studies on the 
long range structural and dynamical properties of CGRP. The aim of this work is to use a 
novel characterization technique to measure the structure and dynamics of the monomeric 
state of CGRP. Such long-range (non-local) properties are expected to have a major 
influence on the affinity and kinetics of binding of IDPs to their receptors, as discussed in 
Chapter One. In order to study the long-range properties of CGRP in aqueous solvent in 
the absence of structure inducing solvents such as TFE, we use tryptophan triplet 
quenching (TTQ). This will also allow comparing such properties to those of a similar 
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peptide previously studied by the Vaiana research group, IAPP, both of which are 
members of the Calcitonin (Ct) peptide family.  
 
2.2. THE CALCITONIN PEPTIDE FAMILY 
 
As there are relatively few studies on the structure of CGRP, comparison of CGRP with 
similar, peptides for which more data is available can help understand the types of 
interactions that determine the structure and dynamics of CGRP. CGRP is a member of 
the Calcitonin peptide family, members of which also include calcitonin, adrenomedullin, 
and amylin (IAPP), among others.4 These peptides are structurally and genetically related 
intrinsically disordered hormone peptides that share a sequence homology ranging from 
about 20 to 50%.4,6 CGRP derives from alternative splicing of the calcitonin gene on 
chromosome 11,1,34 while IAPP, which shares high sequence homology with CGRP, 
comes from chromosome 12, which is thought to be an evolutionary copy of chromosome 
11.4,34 Ct family members, and CGRP and IAPP in particular, share the highest sequence 
homology at the N and C terminal regions.4,35-37 CGRP specifically shares a high 
sequence homology with IAPP, with both 37 aa peptides having 47% of their amino acids 
in common. Figure 2.4 is Uversky plot with CGRP and hIAPP labeled as shown below, 
with both Ct family peptides having a lower net charge and higher hydrophobicity than 
most disordered proteins, despite the lack of regular secondary structure. The structure of 
IAPP has previously been studied using the same technique as in this work by other 
members of the Vaiana research group,38,39 and this work is a continuation of these 
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studies, exploring how variations in the sequence can affect the structure and dynamics of 
these peptides.  
 
 
Figure 2.4. Uversky plot of CGRP and hIAPP. Plot of the mean net charge 
versus mean hydrophobicity of a selection of IDPs and NFPs, with CGRP 
(blue) and hIAPP (maroon) highlighted.  
 
Like CGRP, all members of the Ct family contain a highly conserved disulfide bond at 
the N-terminus of the peptide, which forms a loop that increases binding affinity and is 
required for activation of cell response.4,5,40-42 Previous studies by the Vaiana research 
group found that the N_loop, the loop in IAPP is rigid and found that the structure of the 
N_loop is conducive to aggregation.43 The sequence of the N_loop in CGRP and IAPP 
are very similar and despite having a model for the structure of the N_loop in IAPP, there 
is no direct comparison of the structure of the two peptides in aqueous solvent (under 
near-native conditions). In addition to the N_loop, the C-terminal region in Ct family 
peptides are also always amidated, with the amidation required for receptor binding.4,7,44   
IDPs 
NFPs 
  20 
 
Figure 2.5. Receptor cross-reactivity in Ct family peptides. For each 
receptor, the receptor composition and the order of binding affinity are 
listed (Moore & Salvatore, Brit. J. of Pharm., 2011).7 
 
Interestingly, these peptides which share many similar structural features have very 
different aggregation propensities: some members of the Ct family are prone to aggregate 
while others are remarkably soluble. Calcitonin and IAPP in particular are known to form 
amyloid fibrils in disease; fibrilization of calcitonin is implicated in some thyroid 
cancer45 and IAPP aggregates into fibrils in the pancreas of people with Type II diabetes 
mellitus.35-37 CGRP on the other hand, has never been found in amyloid.35 This suggests 
that while the N and C terminal regions are similar in Ct family peptides, it is the 
differences in the rest of the peptide sequence that must account for the variation in 
receptor binding affinities and aggregation propensity observed in the Ct family.  
 
In addition to being structurally similar, some Ct peptides can bind to the same receptors, 
although with varying affinities.6,7,46 CGRP and its receptors are primarily found in the 
nervous system, while other peptides and receptors of the Ct family are found elsewhere 
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in the body.4,6 Some Ct family members have been shown to bind to the CGRP receptor 
and are able to activate cell response, though with varying efficiency, as shown in Figure 
2.5.4,7,47 Though it is not yet known precisely how receptor binding and activation occurs, 
cross-reactivity between Ct peptides and their receptors is likely due to their sequence 
homology and possible structural similarities. The receptors of the calcitonin family are 
heterodimers composed of two parts: a trans-membrane protein composed of seven trans-
membrane helices, which is a class B G-protein-coupled receptor (GPCR), and a receptor 
activity modifying protein (RAMP) with a single trans-membrane helix.48 The Ct family 
has two GPCRs, the calcitonin receptor (CR) and calcitonin receptor like receptor (CLR) 
that are modified by three receptor modifying proteins: RAMP1, RAMP2, and RAMP3.7  
The combination of the two GPCRs and three receptor modifying proteins allow for 
several possible receptors, each of which Ct family peptides binds to with varying 
potency (Figure 2.5).7  
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Figure 2.6. CGRP and its receptor. CGRP’s receptor is composed of CLR 
with seven trans-membrane helicies and a single helix trans-membrane 
receptor modifying protein RAMP1. CGRP’s C terminal binds to CLR & 
RAMP1 while the N terminal region activates the receptor upon binding to 
CLR (Moore & Salvatore Brit. J. of Pharm., 2011).  
 
In the case of CGRP, CGRP’s primary receptor is composed of the Calcitonin receptor 
like receptor, CLR and receptor modifying protein, RAMP1, as shown in Figure 2.6 
above.7,48 Similar to other Ct family peptides, CGRP’s C-terminal region binds to the N-
terminal regions of CLR and RAMP1 forming an affinity trap, allowing the N-terminal 
region to activate the receptor through interaction with CLR.7 This method of receptor 
activation combined with receptor cross-reactivity likely explains why the N and C 
terminal regions are highly conserved in Ct family peptides. Understanding this receptor 
cross-reactivity in Ct family peptides is important as this cross-reactivity is thought to be 
due to the structural similarities among Ct peptides, and a comparison of the structure and 
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dynamics can help us understand how they carry out their biological function, despite 
being disordered. As there have been no studies of the long-range properties of the CGRP 
monomer and IAPP, which shares receptor cross-reactivity with CGRP, has previously 
been studied by the Vaiana research group, this work studies the CGRP monomer under 
near-native conditions (in the absence of structure inducing solvents), in the same 
solution conditions as IAPP.  
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CHAPTER 3 
CHARACTERIZING INTRINSICALLY DISORDERED PROTEINS 
 
3.1 SUMMARY OF EXPERIMENTAL TECHNIQUES 
 
Intrinsically disordered proteins can be difficult to characterize experimentally, due to 
fast reconfiguration of the protein over short time scales. As IDPs also occupy a wide 
variety of structures, with some IDPs having more secondary structure than others, some 
techniques can used to characterize the protein secondary structure or local contacts 
(contacts between amino acids that are next to each other in sequence). To characterize 
the disordered states of IDPs, other techniques must be used to elucidate non-local 
contact formation (contacts between amino acids that are far apart in the sequence), 
which reports on the tertiary structure and the intra-chain protein dynamics, or the global 
properties, of IDPs. As discussed in Chapter One, non-local and long-range properties are 
expected to have the biggest effect on binding; therefore this work focuses on detecting 
such properties. In this chapter, I discuss various techniques used to characterize IDPs, 
with a focus on the primary technique used in this work to study the structure and 
dynamics of CGRP, tryptophan triplet quenching (TTQ).  
 
3.1.1 CHARACTERIZING LOCAL CONTACTS 
 
The characterization of local contacts such as the secondary structure of the protein will 
give information on the strength and types of intra-molecular bonds present. However, 
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IDPs do not contain large proportions of secondary structure promoting amino acids, and 
any secondary structure they have is likely transient.1,2 In addition, the binding rates and 
tertiary structure of IDPs have not been found to correlate with secondary structure 
content.1,3 The techniques used to measure the secondary structure present in IDPs look at 
the conformation of the backbone of the peptide; such techniques include CD, NMR, and 
Fourier Transform infrared spectroscopy (FTIR).  
 
Circular dichroism is a good method for determining the bulk structure of IDPs in 
solution. CD has been used to measure secondary structure in CGRP4-6 where it was 
found that CGRP has about 20% alpha helical content (as in Figure 2.3). NMR is another 
powerful characterization technique for IDPs, able to resolve the bonds between 
neighboring hydrogen molecules via nuclear Overhauser effect spectroscopy (NOESY), 
and is also able to detect the local structural propensity (alpha helix vs random coil) of 
the backbone via secondary chemical shifts. However, due to CGRP’s rapid fluctuations, 
2-D NMR measurements on CGRP was not able to resolve many sequential NOEs 
without the use of stabilizing solvents.7-9 For more disordered peptides like CGRP, the 
structure stabilizing solvents like TFE and dimethyl sulfoxide (DMSO), while very useful 
in measurements to show structural preferences, are not representative of the structure of 
IDPs in aqueous solution which more closely mimic the environment prior to binding to 
the receptor.  
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Despite the fact that IDPs usually fluctuate on fast timescales, these methods are still 
extremely important in characterizing the structural preferences of disordered proteins 
through local contacts. 
 
3.1.2 CHARACTERIZING NON-LOCAL CONTACTS 
 
Due to fast chain reconfiguration times combined with relatively little secondary 
structure in IDPs, it is important to focus on characterizing non-local contact formation or 
the global structure of IDPs. The formation of non-local contacts, which are contacts 
between residues that are far away in sequence, will significantly restrict the ensemble of 
conformations of an IDP and the dynamics of conformational sampling within the 
ensemble, more so than the formation of a local contact. It is these large changes in the 
ensemble of conformations and in the dynamics of sampling that are expected to affect 
binding affinity and kinetics, as discussed in Chapter One. Recent studies have found 
prior evidence of non-local contacts in IDPs playing an important role in their 
structure.10-12 Measurements on the global properties of IDPs can reveal information on 
the overall structural preferences, such as a preference for compact states (which can 
affect the rate of receptor binding, or conversely, promote aggregation of the protein 
through misfolding). Measurements of the global structure are typically done by 
determining the compactness of the protein through measurements of rh or rG. 
 
Techniques like DLS and pulse field gradient NMR can be used to characterize the global 
structure of IDPs because they give information on the hydrodynamic radius rH, through 
  32 
the measurement of the diffusion of the protein in solution. The size of the protein affects 
the diffusion time and size of the signal, as smaller particles diffuse away more quickly 
and vice versa. However, since these are low resolution techniques, they do not give 
information on the intra-chain dynamics (or the dynamics of conformational sampling). 
In addition, for small IDPS, these techniques require higher concentrations of small 
proteins for good signal quality, thus will not work well for small, insoluble IDPs.  
 
Other techniques measure the radius of gyration, rG, of disordered proteins to determine 
tertiary structural information. SAXS can be used to determine the overall compactness 
of disordered proteins, while paramagnetic relaxation enhancement (PRE) NMR 
measures long-range tertiary contacts between 1-3.5 nm. One of the most powerful 
characterization techniques for IDPs, single molecule Förster resonance energy transfer 
(smFRET) measures tertiary contact formation of disordered proteins. The drawback of 
PRE and smFRET is the use of large bulky dyes that are often very large compared to the 
size of the protein itself.  As these dyes have a distance dependence of 1/r6, this technique 
works well for large, extended proteins but not for short, compact proteins like CGRP.13 
In addition, the dyes can also be highly charged, introducing electrostatic interactions that 
can affect reconfiguration rates and make probing electrostatic effects due to the 
sequence itself difficult. 
 
Despite a few limitations, these techniques that measure the global structural properties 
of IDPs are a powerful way to measure the non-local contacts and structure of disordered 
proteins.  
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3.1.3 CHARACTERIZING DYNAMICAL PROPERTIES 
 
Some techniques measure the dynamical properties of disordered proteins, which in 
conjunction with measurements of the tertiary structural properties can give an full 
picture of the disordered protein. One such technique is NMR relaxation times, which 
gives information on the overall dynamics of the system, where the overall time it takes 
to relax back to the ground state depends on solvent. Fluorescence correlation 
spectroscopy (FCS) is a time resolved technique that measures the diffusion coefficient, 
and is typically used in conjunction with smFRET to give information on both the 
structure and the inter-dye distance fluctuation correlation time for disordered proteins. 
As both of these techniques require the use of large prosthetic dyes that have a 1/r6 
dependence, they have limitations for small proteins. In addition, for small peptides like 
CGRP, the Ro of FRET is large compared to the size of the protein and the highly 
insoluble nature of IAPP makes it very difficult to label with prosthetic dyes, therefore 
this technique cannot be used to compare CGRP with IAPP. 
 
3.2 TECHNIQUES EMPLOYED IN THIS WORK 
 
For a small, highly disordered protein like CGRP, characterization is extremely difficult 
due to the high concentrations or large prosthetic dyes most techniques require. In this 
work, CGRP was characterized using two spectroscopic methods: circular dichroism to 
give information on CGRP’s secondary structural preferences, and tryptophan triplet 
quenching (TTQ) to determine end-to-end contact formation rates for CGRP, which give 
  34 
information on both the structure and dynamics of CGRP. Since this work also builds 
upon previous work on IAPP measured by TTQ,10,14 TTQ was chosen to allow direct 
comparison of CGRP and IAPP. These techniques do not require the use of large 
prosthetic dyes and can be used at low peptide concentrations, ideal for characterizing 
CGRP. They are described in detail below.  
 
3.2.1 CIRCULAR DICHROISM 
 
Circular dichroism is used to determine the secondary structural content of proteins by 
measuring the chirality of the molecule through the difference in absorption between 
right circularly polarized and left circularly polarized light. The instrument sends both 
right circularly polarized light and left circularly polarized light and measures the 
intensity of light that passes through the sample relative to the incident intensity. The 
difference in absorption is the CD signal in millidegrees, denoted by 
 
RL AA −=θ        Eq 1 
 
As the signal θ is dependent on the concentration c, optical pathlength l, and the molar 
extinction coefficient of the protein, the effect of the concentration and pathlength on the 
CD signal is eliminated to get the characteristic molar ellipticity [θ] of the protein. 
 
[ ]
cl ⋅⋅
=
10
θθ        Eq 2 
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To compare the CD signal across various peptides, each amino acid’s individual 
contribution needs to be taken into account by dividing by the number of amino acid 
residues to get the molar ellipticity per residue or MRE. 
 
[ ]
residues
MRE
#
θ
=       Eq 3 
 
Each protein will have a characteristic CD spectrum that is dependent on the amount and 
type of secondary structure present. There are known CD spectrums for random coil, 
alpha helix, beta sheet, polyproline II, and other structures, and the CD signal will be a 
convolution of these spectra, with each component of the signal in proportion to the 
proportion of the secondary structure content.  
 
Circular dichroism experiments to determine secondary structure content are done in the 
near UV (260 to 190 nm). Small sample volumes of only 200uL and low sample 
concentrations of less than 0.2 mg/mL make circular dichroism a powerful way to 
determine secondary structural preferences of disordered proteins. Despite a few 
drawbacks, CD is a powerful way to characterize the secondary structural content of 
small, insoluble proteins and is used in this work to characterize CGRP’s secondary 
structure content.   
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3.2.2 TRYPTOPHAN TRIPLET QUENCHING 
 
3.2.2.1 EXPERIMENTAL BACKGROUND 
 
The primary experimental technique utilized in this paper allows us to simultaneously 
probe the end-to-end distance and the dynamics of contact formation between the two 
ends of the peptide without some of the limitations present in other experimental 
techniques.  TTQ uses the natural phosphorescence of tryptophan, the triplet state of 
which is quenched by cysteine or cystine. As cystine is not an efficient quencher of the 
triplet state of tryptophan,15,16 the quenching reaction is not diffusion limited and the 
disordered protein can reconfigure many times before quenching occurs. The peptide 
therefore explores the ensemble of conformations before quenching and the quenching 
rate yields information on the structure through the equilibrium end-to-end distance P(r) 
and the internal dynamics of the peptide chain through the intra-chain diffusion 
coefficient, D. As TTQ can be used at low millimolar concentrations,17 it is an effective 
technique for insoluble proteins. As TTQ uses the naturally occurring amino acids 
tryptophan and cystine as probes, TTQ does not require large, highly charged prosthetic 
dyes that can significantly perturb small peptides like CGRP. The technique has 
previously been described in detail10,17,18 and a description of how the technique works is 
described as follows. 
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3.2.2.2 THEORY OF OPERATION 
 
Tryptophan is optically excited and a proportion of the excited molecules move to a 
triplet state. The lifetime of this state is long lived (~40 µs)15,16 relative to the time it takes 
for the two ends of a disordered protein to come into contact. If this contact is made for a 
long enough time or for a sufficient number of times, quenching of the excited state will 
occur.  If the two ends do not stay in contact long enough, then they will diffuse away 
without quenching (Figure 3.1).  
 
 
Figure 3.1. Principle of operation. The tryptophan (red molecule) is 
excited, and quenching of the triplet state occurs upon contact with a 
cystine (yellow molecule) after chain reconfiguration.  
 
This can be described empirically as a two state process where the two ends diffuse 
together at a rate kD+, and then either of two things will occur: the triplet state is 
quenched by the cystine at a rate q, or the two ends diffuse away without quenching at a 
rate kD-. The technique measures the observed quenching rate kobs, which is equal to the 
rate that contact is formed times the probability that quenching occurs. 
 
qk
qkk
D
Dobs +
=
−
+       Eq 4 
kD+ 
 
kD- 
 
q 
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Defining the equilibrium constant for forming the encounter complex as Keq = kD+/kD-, 
the observed rate is rewritten in terms of a diffusion-limited rate kD+ and a reaction-
limited rate kR, where kR = q*Keq.  
 
+
+=
DRobs kkk
111
      Eq 5 
 
The reaction-limited rate corresponds to the case where diffusion is fast enough such that 
the fraction of encounter complexes is equal to its equilibrium value at all times. When 
written in this way, the variable that depends on the structure (kR) is separated from the 
variable that depends on the dynamics (kD+).  
 
To obtain the reaction limited and diffusion limited rates, we measure kobs as a function 
of solvent viscosity. In aqueous solution we are close to the reaction limited rate, and at 
very high viscosities, we are close to the diffusion-limited rate. By plotting the inverse of 
the observed rate as a function of solvent viscosity, it is possible to obtain the reaction 
limited and diffusion limited rates (Figure 3.2). 
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Figure 3.2. Viscosity dependence of the observed quenching rate. The 
inverse of the observed quenching rate as a function of solvent viscosity 
for CGRP in 6M GdmCl 50mM NaAc pH 4.9. The intercept at zero 
viscosity is 1/kR, while the slope is 1/ηkD+. 
 
3.2.2.3.SPECTROPHOTOMETER AND DATA COLLECTION 
 
To measure the end-to-end contact formation rates of CGRP, a home-built 
spectrophotometer was constructed in the Laser Spectroscopy and Biophysics Lab (LSBL) 
of Dr. Sara M. Vaiana in the Department of Physics and Center for Biological Physics at 
Arizona State University. Planning and construction was done by Alejandro Solis with 
help from Sebastian Haefner, with further calibration and adjustments done by Stephanie 
Cope, Danmei Bian and Sara Sizemore, all under the supervision of Dr. Sara M. Vaiana. 
A general description of the spectrophotometer setup and collection of the experimental 
data is described below. 
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Prepared samples of IDPs in solution were irradiated by a 10 Hz, 7ns pulse at 290 nm 
generated by an Nd:YAG laser (Continuum) which excites the tryptophan in the protein, 
a proportion of which moves to a triplet state. The quenching of the triplet state of 
tryptophan by cystine was measured by monitoring the triplet-triplet absorption at 458 
nm, with an Argon ion laser (Coherent) at 458 nm continuously irradiating the sample to 
keep the tryptophan in the triplet state until quenching by cystine could occur. A 
schematic of the photophysics is shown in Figure 3.3.  
 
 
Figure 3.3. Photophysics of the triplet state of tryptophan.  
 
As this is a two state process, the triplet-triplet absorption of the sample at 458 nm, which 
corresponds to the population of molecules in the triplet state, decays in time 
exponentially as it is quenched by cystine with a characteristic rate kobs. Fitting this decay 
with a single exponential function gives the observed rate of quenching. To account for 
the decay of free radicals in the solution,10,19 the data were fit to an exponential decay, 
together with a second offset function which varied linearly with log(t) for times greater 
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than 4e-5 s and a time-independent offset constant, as shown in Figure 3.4. A single 
measurement corresponds to the average absorption at 458 nm of 256 events, with five 
measurements performed at each temperature and then averaged.  
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Figure 3.4. Decay of the triplet-triplet absorption at 458 nm. The 
temperature dependence of the triplet-triplet absorption of CGRP in 6M 
GdmCl 50mM NaAc pH 4.9 is fit with a single exponential function with 
a sloped decay at long times. The characteristic decay times from these fits 
are used to calculate the reaction and diffusion limited rates.  
 
 
The temperature of the sample was adjusted by a peltier temperature stage so that 
measurements could be performed as a function of temperature from 5 to 50C. A 
schematic of the setup is shown in Figure 3.5.  
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Figure 3.5. Schematic of the home-built laser pump-probe 
spectrophotometer. The Nd:YAG laser pumps the tryptophan to its triplet 
state at 290 nm, while the argon laser probes the triplet-triplet absorption 
at 458 nm.  
 
 
To extract structural and dynamical information, viscosity and temperature dependent 
measurements were performed by addition of sucrose at each solvent condition (up to 
40% w/v) and performing a temperature scan from 5-50C. The raw data, after correcting 
for background, was assembled into an array of approximately 120 traces, and singular 
value decomposition (SVD) was performed, with the 12 largest components used to 
reconstruct the data. This reduces noise in the signal and decreases uncertainty in the fit, 
without affecting the experimental fit for the observed rate of quenching. To reduce noise 
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further after performing SVD, the data sets for each temperature and viscosity condition 
were averaged. The temperature and viscosity data were then globally fit using the 
exponential decay described above and assuming that the reaction limited kR and 
diffusion limited kD+ rates have a temperature and viscosity dependence that can be 
characterized by  
 
)(Tkk RR =
       Eq 6 
 
)()( 1 TkTk DD +−+ = η
      Eq 7 
 
where η(T) is viscosity of the solvent measured at the given temperature. The values of 
kobs corresponding to the exponential decay of the triplet state are plotted as a function of 
the solvent viscosity, as in Figure 3.2. The temperature and viscosity dependence of kobs 
is given in Eq 8 below.  
 
),(
1
)(
1
),(
1
TkTkTk DRobs ηη +
+=     Eq 8 
 
When analyzed this way, 1/kR is obtained as the intercept at zero viscosity, and 1/ηkD+ as 
the initial slope. These values for kR and ηkD+ for CGRP exhibit Arrhenius-like 
temperature dependence so for easy visualization, Arrhenius plots of the rates are given 
throughout this paper.  
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3.2.2.4. INFORMATION EXTRACTED  
 
Although the quenching of tryptophan was described as a two state model above, the 
actual quenching rate q(r) has a distance dependence. SSS theory models this process in 
which the rate of end-to-end contact formation can be described as 1-D diffusion along 
the end-to-end distance coordinate.20,21 In this way, the observed rate of quenching kobs 
from Eq 5 can be described in terms of kR and kD+ below: 
 
∫=
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In this way, measurements of the reaction and diffusion limited rates allow us to extract 
information on the structure through the equilibrium end-to-end distance distribution P(r) 
and information on the dynamics through the intra-chain diffusion coefficient D. Both kR 
and kD+ have an explicit dependence on temperature,18,22 and with the quenching rate q 
having a complicated dependence on temperature, this work does not attempt to explain 
how CGRP’s structure and dynamics depend on temperature. The temperature 
dependence of kobs was measured in order to do global fits of the experimental data, and 
in this work, kobs, kR, and ηkD+ will be plotted on Arrhenius plots to guide the eye only, 
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and we will not attempt to give interpretations of the enthalpy, ∆H, and instead will only 
discuss shifts in the rates that occur at all temperatures. 
 
Despite the fact that IDPs are unfolded with little regular structure, their end to end 
distances can vary significantly from one IDP to another, and can experience significant 
compaction or expansion under different solvent conditions.  In order to quantify these 
changes in structure, we can use basic polymer models to calculate how the end to end 
distances change. For the analysis in this work, we use the ideal chain or Gaussian model, 
in which the monomer is divided into segments of equal lengths, or effective segment 
lengths, b. In this model, each segment is uncorrelated and freely rotating, effectively 
approximating a 3-D random walk, with the average end-to-end distance √<r2> taking the 
form 
 
bNr 2
12
=       Eq 11 
 
where N is the number of segments, or amino acids, making up the polymer. Although a 
Gaussian model is idealized, other groups have found that a Gaussian P(r) is sufficient to 
describe changes in √<r2> when performing end-to-end contact formation 
measurements,23,24 so for the purposes of this work, all end-to-end distances are 
calculated assuming a Gaussian P(r). 
 
Tryptophan triplet quenching when used in conjunction with SSS theory and polymer 
models, is a powerful way to characterize the structure and dynamics of disordered 
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proteins in solution. Through the deployment of the techniques described in this chapter, 
this work seeks to characterize the structure and internal dynamics of CGRP to help 
understand how the monomer state of CGRP interacts with itself and its receptor.  
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CHAPTER 4 
CGRP IN AQUEOUS SOLVENT AND DENATURANT 
 
4.1. INTRODUCTION 
 
The aim of this work is to understand the types of intra-chain interactions which 
modulate the structure and dynamics of CGRP, in order to better understand the types of 
interactions that might drive receptor binding and activation. It is thought that the high 
cross receptor cross-reactivity among Ct peptide family members1-3 are due to their 
structural similarities.  In particular, the focus of this work is the study of the structure 
and dynamics of CGRP, whose structure, as Chapter Two reveals, is relatively unknown 
and unexplored. Therefore it is interesting to compare the structure of CGRP with IAPP, 
a Ct family peptide that has been studied extensively, with which CGRP shares a 47% 
sequence homology.4-6 As CGRP is very soluble compared to IAPP4 and has very similar 
sequence composition, comparison of the structure and dynamics of the two peptides can 
allow us to explore differences and similarities in the method of receptor binding and 
activation.  
 
We first set out to understand what structural and dynamical similarities exist between 
the Ct family peptides CGRP and IAPP that allow for receptor cross-reactivity. As 
mentioned in Chapter Two, all Ct family peptides have a characteristic N-terminal 
disulfide loop, N_loop, which is required for activation of cell response.6-10 The loop 
could promote interactions between the peptide chain and the receptor, which is 
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supported by studies that show that removal of the N_loop or conversion to a linear 
analog by breaking the disulfide bond abolishes receptor activity.8-10 Previous 
experiments and molecular dynamics simulations showed that the N_loop causes both 
human and rat IAPP variants to prefer a collapsed state in aqueous solvent, with the 
N_loop forming favorable non-local intra-chain interactions with the rest of the chain.11 
Earlier work in the Vaiana Lab group found that the N_loop readily self-associates, 
forming favorable inter-chain interactions, suggesting a potential mechanism for receptor 
binding and aggregation.12 All of this hints at an important role that the characteristic 
N_loop found in Ct family peptides likely plays in their structure and function, and might 
be a potential mechanism for pathological aggregation.  
 
Circular dichroism measurements done on both CGRP and IAPP show that CGRP and 
IAPP have very different secondary structure content in aqueous solvent, with CGRP 
having more alpha helix than IAPP, which appears to preferentially adopt a random coil 
structure.13 In addition, CD and NMR measurements show that when the loop found in 
CGRP and IAPP is truncated, both peptides lose their alpha helical propensity.13-15 This 
suggests that CGRP, despite having a similar sequence to IAPP, might have more helix 
promoting residues, and that the N_loop in the Ct family peptides help stabilize the 
transient secondary structure.  
 
In this chapter, tryptophan triplet quenching measurements on CGRP in both buffer and 
denaturant as well as circular dichroism measurements were performed to explore both 
the effect of the solution environment on the secondary and tertiary structure of CGRP 
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and to compare it with previous measurements on IAPP in the same solution conditions. 
TTQ studies on the disulfide loop found in CGRP were also performed to explore how 
the structure of CGRP depends on the N_loop. In this way, we explore how peptides of 
the same length in the same solvent, with 47% sequence homology, adopt different 
structural characteristics.  
 
4.2. EXPERIMENTAL METHODS 
 
MATERIALS 
Fmoc(9-fluorenylmethoxycarbonyl)-protected amino acids were purchased from 
Novabiochem. HOBt (N-hydroxy benzotriazole) and HBTU (O-Benzotriazole-N, N, N’, 
N’-tetramethyl-uronium-hexafluoro-phosphate) were purchased from Genscript. N,N- 
iisopropylethylamine, or Hünig's base (DIPEA), and N-Methyl-2-pyrrolidone (NMP), 
used as base in solid phase peptide synthesis, were purchased from Sigma Aldrich.  
Piperidine (Sigma-Aldrich) was used for deprotection. Rink Amide ChemMatrix® was 
purchased from Matrix Innovations. Dimethyl formamide, Dichloromethane and 
Acetonitrile were purchased from Fisher Scientific and were used without further 
purification.  
 
In addition, >95% purity CGRP wild-type and CGRP D3N mutants, both with the F37W 
mutation, were purchased from Genscript and purity verified via HPLC on a C18 
analytical column. Circular dichroism and TTQ measurements on CGRP F37W 
purchased from Genscript was identical to measurements on CGRP F37W that was 
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synthesized and purified as described below, and show no difference in secondary or 
tertiary structure between the two sources.  
 
PEPTIDE SYNTHESIS AND PURIFICATION 
CGRP F37W was synthesized on a 0.1 mmol scale using a CEM Liberty Automated 
Microwave Peptide Synthesizer and PALChem Matrix resin. After synthesis, the peptide 
was thoroughly washed 5 times by DMF followed by DCM. After washing, the peptide 
was stored on the resin at -20°C. For deprotection, the peptide was shaken for one hour in 
20% piperdine, 0.1M HOBt in DMF. The cleavage cocktail consisted of 81.5% 
trifluoroacetic acid + 5% Water +5% Anisole + 5% Thioanisole + 2.5% 1,2-Ethanedithiol 
+ 1% triisopropylsilane at the ratio of 150 µL/ 10 mgs of resin. CGRP F37W was purified 
using reverse phase high performance liquid chromatography (HPLC) on a Waters 600E 
system. Crude peptide was purified on a C4 semi-preparative column (Vydac/Grace 
Deerfield, IL) from 5-50% Acetonitrile with 0.1% (v/v) TFA at a gradient of 1% every 
three minutes. 
 
DISULFIDE FORMATION AND FURTHER PURIFICATION 
1.0 mM of lyopholized peptide was dissolved in 30% DMSO and 3% Acetic Acid. The 
sample was stirred with a magnetic stir bar at 800 rpm. During this time, the formation of 
the intra-molecular disulfide bonds was monitored via HPLC on a C18 analytical column. 
The reaction was deemed complete when the reduced peptide’s HPLC peak was no 
longer apparent: approximately 12 hours. After this time, the sample was frozen and 
  54 
lyophilized. Oxidized peptide was re-purified on a C18 semi-preparative column to 
further purify and separate any un-reacted peptide. 
 
Calibrated matrix-assisted laser desorption/ionization - time of flight mass spectrometry 
(MALDI-TOF) mass spectrometry indicated the presence of a -2 Da species (above the 
margin of error the instrument), corresponding to the oxidized form of the peptide. To 
further support these findings, a maleimide sulfhydryl reaction was performed. 1 mg 3-
(N-Maleimidopropionyl)-biocytin (Cayman Chemical Company Ann Arbor, MI) was 
dissolved in 180uL 20mM PBS buffer, pH=7.0 and 20µL acetonitrile. 1mg pure, oxidized 
CGRP F37W was dissolved in 90µL 20mM PBS buffer, pH=7.0 and 10µL acetonitrile. 
This solution was combined with the 3-(N-Maleimidopropionyl)-biocytin solution and 
shaken for four hours. At 1 hour increments, 20 µL aliquot was removed and frozen in 
dry ice.  After four hours, the four aliquots were analyzed via MALDI-TOF. 
 
HPLC peaks were analyzed by a Voyager Systems 4320 (Applied Biosystems) MALDI-
TOF. The peak corresponding to a molecular weight of 3828Da (corresponding to the 
amidated and oxidized form of CGRP F37W) was analyzed further for purity by 
analytical HPLC, using a reverse phase C18 analytical column 214TP54 (Length 250mm 
× ID 4.6mm) particle size 5µm using the same gradient conditions with 0.9 mL/min flow 
rate. A single peak eluting at a gradient corresponding to the hydrophobicity of CGRP 
was collected, immediately frozen in liquid nitrogen, lyophilized, and kept at -20°C. 
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END TO END CONTACT FORMATION BY TRYPTOPHAN TRIPLET 
QUENCHING 
The quenching of the triplet state of tryptophan by cystine in 100uM CGRP samples were 
measured in either 50mM NaAc at pH 3 or 4.9, or 20mM NaPO4 pH 8 buffers (Sigma-
Aldrich). The pHs of the buffers were checked by an Accumet BASIC AB15 pH meter 
(Fisher Sci) and the final solution pH was adjusted using either 1M NaOH or 1M HCl as 
needed. In order to measure CGRP in denaturant and to do viscosity dependent 
measurements, guanadinium chloride, or GdmCl (as measured by calculated molar 
concentration) and/or sucrose (as measured by percent weight by volume) were added to 
prepared buffer and the pH readjusted as needed. The buffers were kept at 4C and filtered 
with a 0.02 um Whatman Anotop 10 filter before further sample preparation. Lyophilized 
peptide was weighed out to yield 100uM in ~3 mL of sample (~0.38 mg/mL) and added 
directly to freshly filtered buffer. Absorbance was checked in a 1cm quartz cuvette using 
an extinction coefficient of ε = 5774 m2/mol, and the concentration adjusted to 100uM if 
needed. The CGRP samples were filtered directly into long-neck quartz cuvettes (Starna 
Cells) with a Whatman Anotop 10 0.2 um filter, and degassed with nitrous oxide for at 
least two hours to eliminate free oxygen from the sample before measurement. 
 
For TTQ measurements of CGRP in TCEP-HCl (tris(2-carboxyethyl)phosphine 
hydrochloride), samples of CGRP at pH 4.9 in both buffer and 6M GdmCl were prepared 
as above. However, before degassing, a two-fold (200µM) excess of TCEP (Pierce) was 
weighed out and added directly to the CGRP samples and stirred gently.  
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For TTQ experiments on CGRP C7S and C2S, due to the possibility of oxidization of the 
cysteines, both the peptide and buffer are deoxygenated before the addition of peptide to 
buffer, with sample preparation proceeding as usual afterwards. 
  
The triplet-triplet absorption of the sample at 457 nm, which corresponds to the decay of 
the triplet state of tryptophan as it is quenched by cystine, was measured with New Focus 
Model 1621 nanosecond photodetectors, and the data recorded by Tektronic DP03032 
digital phosphor oscilloscopes. The temperature of the sample was adjusted by a 
Quantum Northwest TLC50 turret peltier stage so that measurements could be performed 
as a function of temperature from 5 to 50C.  
 
As CGRP does not have a naturally occurring tryptophan, the phenylalanine at residue 37 
was mutated to a tryptophan that will be quenched by the naturally occurring cystine at 
the N terminus. As both amino acids have aromatic rings, the structure of CGRP is not 
expected to be significantly perturbed by this mutation. This was checked by comparing 
the circular dichroism structure of CGRP F37W to already published spectra from 
literature.13,16 No change in CGRP’s secondary structure was observed due to this 
mutation. In addition, NMR studies that actually truncated the chain by removing the 
phenylalanine at residue 37 saw no change in structure, and was still able to bind to the 
CGRP receptors although biological activity was abolished.17 Because of this, it is 
assumed that little to no change in the structure of CGRP occurs due to this mutation. 
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CIRCULAR DICHROISM SPECTROSCOPY 
CD Spectra of the samples were measured in 1mm quartz cuvettes (Starna Cells).  
Aliquots of solutions prepared for TCQ were diluted with Millipore H2O, resulting in 
final peptide concentrations ranging from 10-40 µM. Samples were measured by a Jasco 
J-710 spectropolarimeter (Jasco Company) with a 1 nm bandwidth.  For each sample, 
eight spectra taken with a 0.2 nm pitch at a 50 nm/min scan speed were averaged.  Before 
data analysis, spectra were buffer subtracted.  
 
4.3 THE CGRP MONOMER SAMPLES STATES WITH SHORT END-TO-END 
DISTANCES IN SOLUTION 
 
4.3.1. OBSERVED RELAXATION RATE OF CGRP 
 
Using tryptophan triplet quenching, the observed quenching rate kobs of CGRP was 
measured, which is the rate that cystine quenches the triplet state of tryptophan. This rate 
kobs is equal to the rate that the two ends of the peptide chain come into contact, kD+ times 
the probability that quenching occurs. As this rate depends on the volume of the chain, 
kobs can be used as a first approximation of the expansion or compaction of the chain. The 
observed quenching rates of CGRP in both 50mM NaAc buffer pH 5 and in 6M GdmCl 
are shown on an Arrhenius plot in Figure 4.1. We see that CGRP has a three fold increase 
in rates when going from denaturant (6M GdmCl) to buffer, indicating that CGRP 
samples highly compact states (characterized by short end-to-end distances) in aqueous 
solvent relative to denaturant. 
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Figure 4.1. Arrhenius plot of the observed quenching rate of CGRP. 
CGRP was measured in 50mM NaAc pH 4.9 buffer (orange) and 
denaturant (6M GdmCl- blue).  
 
This collapse means that CGRP has intra-chain interactions that form non-local contacts 
in aqueous solvent, such as electrostatic interactions and hydrophobic interactions. To 
further explore CGRP in both buffer and denaturant, viscosity dependent measurements 
must be performed.  
 
4.3.2. STRUCTURE AND DYNAMICS OF CGRP 
 
To determine whether the increase in kobs in buffer is due to chain collapse rather than 
faster chain dynamics, kobs was measured as a function of viscosity and kR and ηkD+ were 
obtained from the intercept and slope, as described in Chapter 3.2.2. Figure 4.2 shows the 
inverse of the observed quenching rate as a function of solvent viscosity for CGRP in 
buffer 
6M GdmCl 
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both buffer and denaturant. The reaction limited rate is extracted from the intercept at 
zero viscosity, and the diffusion limited rate is the initial slope.  
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Figure 4.2. Viscosity dependence of the observed quenching rate of CGRP 
in buffer and denaturant. The figures plot the temperature dependence of 
the inverse of the observed quenching rate of CGRP as a function of 
solvent viscosity in buffer (A) and denaturant (B).  
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Arrhenius plots of both the reaction limited rates and diffusion limited rates of CGRP 
obtained from analysis of Figure 4.2 above in buffer and denaturant are shown in Figure 
4.3A and 4.3B respectively. In this chapter we will only focus on the reaction limited 
rates while the diffusion limited rates will be discussed in Chapter Six. The plot in Figure 
4.3.A shows that the three fold increase in kobs when going from denaturant to buffer are 
also seen in kR, confirming the conclusions drawn in the previous section that the 
increase in rates is due to chain compaction rather than faster chain dynamics. In the next 
section, these experimental values for kR will be used to estimate the increase in the end-
to-end distance of CGRP in buffer and denaturant (Table 4.2). To further explore and 
quantify the types of attractive interactions on the structure of CGRP, measurements of 
CGRP in different pH, salt and denaturant conditions must be performed. In Chapter Five, 
I will present the results of these measurements.  
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Figure 4.3. Arrhenius plots of the reaction limited (A) and diffusion 
limited (B) rates of CGRP. CGRP was measured in 50mM NaAc pH 4.9 
buffer (orange) and denaturant (6M GdmCl- blue).  
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4.3.3. COMPARISON OF CGRP WITH IAPP 
 
The reaction limited rate of CGRP in both buffer and denaturant were then compared to 
analogous experimental data of IAPP from Vaiana et al, 2009, in the same solution 
conditions.11 The rates of CGRP compared  IAPP at 20C in both buffer and denaturant 
are presented in Table 4.1. In both buffer and denaturant, CGRP has smaller values of kR 
corresponding to a more expanded chain than IAPP. 
 
Peptide Solvent kobs (µs-1) kR (µs-1) 
Buffer 0.57 ± 0.06 0.93 ± 0.09 
CGRP 
6M GdmCl 0.19 ± 0.02 0.25 ± 0.03 
Buffer 0.92 ± 0.09 1.3 ± 0.12 
hIAPP 
6M GdmCl 0.22 ± 0.02 0.32 ± 0.03 
 
Table 4.1. kobs and kR for CGRP and IAPP in buffer and denaturant at 20C.  
 
 
 
 
The data are also presented in an Arrhenius plot of the temperature dependence of the 
reaction limited rates (Figure 4.4). As evident in Figure 4.4 and easily observed in Table 
4.1, while CGRP populates compact states in aqueous solvent (a three fold increase in kR 
compared to the expected 1.8 fold increase in kR for an ideal chain),18 CGRP still has a 
smaller increase in kR than observed in IAPP (which has a five fold increase in kR when 
going from denaturant to buffer).  
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Figure 4.4. Arrhenius plot of the reaction limited rates of CGRP and IAPP. 
Both peptides are in both 50mM NaAc pH 4.9 buffer or denaturant (6M 
GdmCl)- CGRP in 6M GdmCl (closed blue circles), IAPP in 6M Gdmcl 
(open blue circles), and CGRP in buffer (closed orange circles,) and IAPP 
(open green circles).  
 
 
Using the measured values of kR for CGRP (and those previously measured for IAPP) we 
can estimate the relative end-to-end distances, for example in the simple case of a 
Gaussian P(r) distribution. In this way we can quantify how much more compact CGRP 
is in aqueous solvent than in denaturant.  
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The Gaussian model does not take into account excluded volume interactions, but has 
been found to be a good first approximation in disordered proteins. Analyzing the 
reaction limited rates found for CGRP in buffer and denaturant using a Gaussian model 
give the average end to end distances found in Table 4.2.  
 
Peptide Solvent 2r (nm) 
Buffer 2.39 
CGRP 
6M GdmCl 3.72 
Buffer 2.14 
IAPP 
6M GdmCl 3.43 
 
Table 4.2 End-to-end distances of CGRP and IAPP in buffer and 
denaturant 
 
 
 
 
We see that the end-to-end distance of CGRP increases from 2.4 nm to 3.7 nm in buffer 
and denaturant, respectively. In Figure 4.5, comparison of the equilibrium end-to end-
distance calculated using the previously published reaction limited rates for IAPP11 show 
that while in denaturant CGRP has a similar √<r2> to IAPP, CGRP is more expanded 
than IAPP in buffer (2.4 vs 2.1 nm), supporting the conclusion that in buffer, IAPP has 
larger attractive intra-chain interactions than CGRP. 
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Figure 4.5. The equilibrium end-to-end distance distribution of CGRP 
(orange- buffer, solid blue line- 6M GdmCl) and IAPP (green dashed line- 
buffer, blue dashed line- 6M GdmCl) assuming a Gaussian P(r). 
 
 
To further understand the structural differences between CGRP and IAPP, the CD 
spectrum of CGRP was measured and compared to that of IAPP. Circular dichroism 
measurements on both CGRP and rat IAPP (rIAPP) in aqueous solvent (50mM NaAc pH 
4.9) show that CGRP adopts more alpha helix than rIAPP which is primarily random coil 
(Figure 4.6). CD measurements were done on rIAPP because human IAPP aggregates 
readily, and previous studies have shown little difference in secondary structure between 
human IAPP (hIAPP) and rIAPP.19 
IAPP 
  CGRP 
6M GdmCl 
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Figure 4.6. CD spectra of comparing CGRP and rIAPP. The CD spectra of 
CGRP (orange) has a larger shoulder at 220 nm than rIAPP (green).  
 
 
 
Figure 4.6 supports previous CD studies that found that CGRP has about 20% alpha 
helix.13,16,20 The peptide with greater apparent helical content (CGRP) therefore has a 
larger end-to-end distance than the peptide with a higher percentage of random coil 
(IAPP); this might suggest that the greater alpha helical content might lead to a stiffer 
chain.  We note however that Marsh and Forman-Kay showed that the amount of 
compaction in disordered peptides does not correlate with secondary structure content 
and is primarily due to electrostatics and hydrophobic effects.21   
 
4.4 N_LOOP CONTRIBUTES TO COLLAPSE IN CGRP 
 
To explore why CGRP populates collapsed states in buffer, a closer look at the sequence 
of CGRP was required. The most significant structural feature of CGRP is the disulfide 
rIAPP 
 
CGRP 
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bond forming a loop between the cysteine residues at 2 and 7 (N_loop). Vaiana, et al 
found that by attaching the disulfide loop, residues 1-8 of IAPP, which differs from 
CGRP’s by only three residues (Figure 2.2), to a model peptide with no hydrophobic or 
charged residues CC(AGQ)9W , the reaction limited rates increased seven fold from 
denaturant to buffer.11 A seven fold increase in the reaction limited rate means that there 
is a large collapse in buffer, which was surprising as the same sequence without the loop 
only had a roughly 1.8 fold increase in rates when going from denaturant to buffer (as 
expected from polymer models of peptides of the same length).18 As this model peptide 
does not have any obvious hydrophobic or attractive intra-chain interactions, this collapse 
must be due to interactions between the N_loop and the disordered chain. Since this 
collapse is present in both the model peptide and in IAPP, which have significantly 
different sequences, these interactions must be between the side chains and backbone of 
the N_loop and the backbone atoms of the disordered chain. Molecular dynamics 
simulations showed that residues 3 and 4 of the N_loop are especially favorable to 
forming side chain and backbone interactions with the backbone of the rest of the chain, 
especially with amino acids near the N_loop, with these interactions effectively 
decreasing the chain length and therefore increasing the rate that the two ends come into 
contact.11 Cope, et al found that the N_loop by itself strongly self associates,12 supporting 
the argument that the rigid structure of the N_loop in Ct family peptides reduces the 
entropy cost for the formation of intrachain hydrogen bonds.  
 
To test whether a similar mechanism was at play in CGRP, the quenching rate of linear 
analogs of CGRP were measured. A twofold excess of TCEP was added to the intact 
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form of CGRP in both aqueous solvent and denaturant, breaking the disulfide bond by 
oxidative reduction. In addition, TTQ experiments were performed on two mutants where 
a serine residue was substituted for each of the cysteine residues, so that the cysteine 
quencher is in position 2 in one peptide (CGRP C7S), and position 7 in the other (CGRP 
C2S). In both of these experiments, the observed quenching rate increased only by a 
factor of two when going from denaturant to aqueous solvent; the results are discussed in 
more detail below.  
 
In TCEP at 5C, CGRP’s observed quenching rate increases two fold when going from 
denaturant to aqueous solvent, which is smaller than the three fold increase observed for 
wild type CGRP with the intact N_loop (Table 4.3). We note that TTQ measurements on 
CGRP reduced by TCEP in buffer and denaturant have significantly larger observed rates 
than CGRP with the intact N_loop due to the fact that two quenchers are now present (the 
cysteines at position 2 and 7). This makes quantitative analysis more complicated than in 
the case of a single quencher. 
Peptide Solvent kobs (µs-1) kobs (buffer) kobs (GdmCl) 
Buffer 0.34 ± 0.03 
CGRP 
6M GdmCl 0.11 ± 0.01 
3.1 
Buffer 0.42 ± 0.04 CGRP w/ 
TCEP 6M GdmCl 0.20 ± 0.02 
2.1 
  
Table 4.3. Observed quenching rate of CGRP with and without TCEP at 
5C. The ratio of kobs in buffer versus denaturant is related to the 
compaction of CGRP in buffer. 
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To avoid the complications due to the presence of two quenchers, the cysteine at position 
2 or the one at position 7 was replaced with a serine to produce CGRP C2S and CGRP 
C7S respectively. With this mutation, the linear analog of CGRP now has one quencher 
provided by a substitution that is not expected to change its conformation. The location of 
the quencher along the peptide chain is also not expected to significantly alter the 
quenching efficiency or prohibit comparison of kobs between CGRP variants.18 For 
completeness however, experiments were performed with both of these mutations in both 
denaturant and buffer to compare to CGRP wild type, to eliminate the effects that the 
type and position of the quencher might have on the observed quenching rates.  
 
Peptide Solvent kobs (µs-1) kobs (buffer) kobs (GdmCl) 
Buffer 0.59 ± 0.06 
CGRP 
6M GdmCl 0.19 ± 0.02 
3.1 
Buffer 0.43 ± 0.04 
CGRP C7S 
6M GdmCl 0.21 ± 0.02 
2.1 
Buffer 0.48 ± 0.05 
CGRP C2S 
6M GdmCl 0.22 ± 0.02 
2.2 
 
 
Table 4.4 kobs of CGRP wt, C7S, C2S at 20C in buffer and denaturant 
 
Experimental measurements of the observed quenching rates of the linear analogs of 
CGRP, CGRP C2S and C7S at 20C, in both buffer and denaturant are shown in Table 4.4. 
The observed quenching rates of C7S and C2S in denaturant are similar to CGRP wild 
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type, however the linear analogs of CGRP show only a twofold increase in rates when 
going from denaturant to buffer, compared to the threefold increase in rates found in 
CGRP wild type.  
 
Our data therefore suggests that a mechanism similar to the one proposed for IAPP might 
contribute to the collapse of CGRP in buffer. The N_loop has also been shown to 
stabilize the alpha helical content, with a linear analog, CGRP8-37 with vastly decreased 
secondary structure.14,15 Both these mechanisms could be important for the binding of 
CGRP to its receptor, since in addition to increasing binding affinity, the intact N_loop is 
required in order to activate cell response.8-10  
 
We note that the difference in the observed quenching rates for these linear analogs of 
CGRP are similar to the 1.8-fold increase in rates between denaturant and buffer 
observed by Buscaglia, et al 2006, for the model peptide C(AGQ)9W, which was shown 
behave like a worm-like chain good solvent (denaturant) versus bad solvent (water).18  
This is very close to our observed factor of 2.1-2.2 for the linear analogs of CGRP 
suggesting that in the absence of the N_loop , the peptide behaves similarly to the model 
peptide C(AGQ)9W and that the presence of the disulfide bond in N_loop is responsible 
for most of the increase in rates.  
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4.5. DISCUSSION 
 
Our findings show that CGRP adopts more compact states in buffer than in denaturant, 
with kR increasing threefold in buffer compared to denaturant instead of the expected two 
fold increase for a polymer of the same length. As kR depends on the equilibrium end-to-
end distance, CGRP is significantly more compact than expected in buffer which is likely 
due to attractive non-local intra-chain interactions present in CGRP. CGRP also does not 
become as compact as a similar peptide IAPP, despite sharing 47% sequence homology. 
CD measurements also show that CGRP has more secondary structure in aqueous solvent 
than IAPP. It was also shown that the disulfide loop (N_loop: residues 1-8) found at the 
N-terminus of CGRP accounts for some of this collapse, possibly through the formation 
of interactions with the rest of the peptide chain, similar to the mechanism seen in 
IAPP.11    
 
The observed differences between the structure of CGRP and IAPP must be due to 
differences in the sequence. CGRP shares a 47% sequence homology with IAPP, 
however IAPP aggregates into amyloid fibrils while CGRP is otherwise soluble.4-6 A 
glance at the sequence composition of CGRP and IAPP in Figure 4.7 does not reveal 
significant differences in the average side-chain excluded volume, but CGRP does have a 
higher average side-chain hydrophobicity despite being more expanded than IAPP. 
However, CGRP does have a higher net charge with charges distributed relatively equally 
along the chain compared to IAPP, which has a smaller net charge with charges clustered 
around the N-terminal region (as evidenced in the Uversky plot in Figure 2.4).  
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Figure 4.7. Sequence and charge composition of Ct family peptides. The 
positively charged amino acids at pH 4.9 are indicated with red letters, 
while the negatively charged amino acids are indicated with green letters. 
Both CGRP and IAPP have a disulfide bond between residues 2 and 7, and 
both have an amidated C-terminus.  
 
 
Therefore it is possible that electrostatic interactions, rather than hydrophobic interactions, 
could account for the observed differences between CGRP and IAPP. The effect of 
electrostatic interactions on the structure and dynamics of CGRP as well as a closer 
comparison between CGRP and IAPP’s structure and dynamics will be explored in 
Chapters Five and Six, respectively.  
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CHAPTER 5 
EFFECTS OF CHARGE INTERACTIONS, SALT SCREENING, AND 
DENATURANT EXPANSION ON THE STRUCTURE OF CGRP 
 
5.1. INTRODUCTION 
 
The results in the previous chapter showed that CGRP adopts compact states in aqueous 
solvent compared to denaturant, with the disulfide loop at the N-terminus of CGRP 
potentially causing some of this collapse through the formation of attractive intra-chain 
interactions, as previously seen in IAPP.1 In this chapter, we study the effects of 
electrostatic interactions, salt screening, and denaturant expansion on the structure of 
CGRP and rationalize them in terms of sequence specific effects and potential 
mechanisms for biological activation.  
 
Due to the fact that electrostatic interactions are the strongest kinds of interactions that 
occur at long distances, electrostatic interactions have long been known to greatly affect 
protein structure in folded proteins as well as the binding of proteins to their receptors.2-4 
It is also well known that electrostatic interactions influence aggregation rates;5,6 for 
example, a study found that the lag time of IAPP (or the time it takes for fibrilization to 
occur) decreased when IAPP is in strongly ionic solutions.7 In addition, recent studies 
have shown that electrostatic interactions also appear to affect the structure of disordered 
proteins, despite the fact that they are not folded. Marsh and Forman-Kay’s 2010 review 
of IDPs pointed out that electrostatics appears to be a primary determinant of chain 
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expansion of disordered proteins.8 Other studies of IDPs show that both the secondary 
and tertiary structure content are highly sensitive to addition of counterions in solution.3,7 
This interplay between the protein and an ionic solvent has already been seen in the 
diffusive binding of two folded proteins, with the binding rate of the two proteins 
strongly correlating with the Debye length of the solution.2 While the mechanism for how 
electrostatic interactions affect the aggregation propensity of IAPP is unknown, it is 
likely that charge screening allows other attractive intra-chain interactions that promote 
oliogmerization and fibrilization of IAPP.  
 
Other studies on disordered and unfolded proteins showed that some proteins have a 
complicated interplay with the solvent, which is largely dependent on their net charge. In 
the case of the N-terminal domain of HIV-1 integrase, which folds only upon binding of 
Zn2+ ions but is otherwise disordered and human prothymosin α (ProTα), a highly 
charged IDP, GdmCl was shown to exhibit both a charge screening and denaturant 
expansion effect on disordered proteins, while non-ionic denaturants, such as Urea, show 
only denaturant expansion.9,10  These proteins were found to compact due to charge 
screening at low GdmCl concentrations, with denaturant expansion effect taking over at 
higher concentrations. It was found that these proteins can be modeled as polyampholytes, 
where the proportion of charged residues as well as the net charge on the chain are 
important, with more collapsed structures in proteins with an even mix of positive and 
negative charges along the sequence.11,12 However, other studies have pointed out the 
importance of charge patterning in polymer models, rather than just net charge.12,13 
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Whether simple polymer models are sufficient to describe the behavior of IDPs is still 
under debate and is something that needs to be quantitatively modeled for IDPs. 
 
This chapter sets out to understand why CGRP, despite having a high sequence homology 
with IAPP with similar net charge and hydrophobicity, is less compact than IAPP in 
aqueous solvent. To do this, the effect of electrostatic and solvent interactions in CGRP is 
explored through specific site directed mutations and by changing the solution 
environment of CGRP through changing the solvent pH and the addition of counter-ions 
and denaturant. These studies are important because as I will more fully discuss at the 
end of this chapter, the release of CGRP is known to be triggered by tissue acidosis and 
the presence of excess ions in the extracellular region of cells. Possible changes in the 
structure or the dynamics of the unbound CGRP monomer due to variations in pH or salt 
concentration can affect the affinity and rate of binding of CGRP to its receptor, which is 
relevant to its biological function. As the results of this chapter show, CGRP is highly 
sensitive to the solution environment and that electrostatic interactions modulate the 
dimensions of CGRP. 
 
5.2. EXPERIMENTAL METHODS 
 
The experimental methods were previously described in Chapter Four, but with the 
following modifications: 
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MATERIALS 
Peptide with >95% purity (CGRP wild-type and CGRP D3N mutants, both with the 
F37W mutation) were purchased from Genscript or synthesized as described previously. 
All peptide used in these experiments were stored in the lyophilized state at -20C before 
use. 
 
TRYPTOPHAN TRIPLET QUENCHING MEASUREMENTS 
Samples were prepared for TTQ and data were analyzed as described previously. For pH 
3 and pH 4.9 experiments, 50mM sodium acetate buffer was used, and pH 7 and 8 
experiments were in 20mM sodium phosphate buffer. To explore the solvent effects on 
CGRP through the addition of solutes, sucrose (as measured by percent weight by 
volume), potassium chloride (KCl), GdmCl and Urea (as measured by calculated molar 
concentration) were added to the buffer and the final solution pH was adjusted using 
either 1M NaOH or 1M HCl as needed.   
 
CIRCULAR DICHROISM MEASUREMENTS 
To measure the CD spectra of CGRP, samples were prepared and measured as before, 
with a few differences in the sample preparation when titrating the solvent. For CD 
measurements that titrate the solvent, two stock samples of ~30 uM peptide were 
prepared as for TTQ measurements, but at both the high and low solvent concentrations 
for use as stock solutions. The stock solutions were combined at the proper ratio to get 
200uL of sample at each solvent concentration desired, in order to fully titrate the CD 
spectra of the peptide with respect to the solvent.  
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5.3. COMPACTION OF CGRP DEPENDS ON NET CHARGE 
 
5.3.1. CGRP EXPANDS AS NET CHARGE INCREASES 
 
To explore the effect of electrostatic interactions on the structure of CGRP, the net charge 
on CGRP was changed by adjusting the solvent pH. A look at Figure 2.2 shows that 
CGRP has two charged residues that can easily be titrated: the aspartic acid at C3 and the 
histidine at C11. By measuring the quenching rate of CGRP at pH 3, pH 4.9 and pH 8, we 
effectively change the net charge on CGRP from +6 to +4 and in this way explore the 
effect of electrostatic interactions on the structure of CGRP.  
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Figure 5.1. The pH dependence of the reaction limited rates of CGRP at 
pH 8 (green), pH 4.9 (orange), pH 3 (red) and 6M GdmCl (blue).  
 
 
Buffer 
6M GdmCl 
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Arrhenius plots of CGRP at +4 (pH 3), +5 (pH 4.9) and +6 (pH 8) net charge are 
presented in Figure 5.1. Here kR decreases when the net charge increases, with CGRP at a 
net charge of +4 populating states with shorter end-to-end distances than with a net 
charge of +6. Table 5.1 shows the pH dependence on the end-to-end distance of CGRP at 
20C assuming a Gaussian chain, where the end to end distance increases from a compact 
2.10 nm to 2.80 nm in buffer due to changes in the net charge of CGRP. Interestingly, 
even at a +6 net charge, CGRP is still more compact than in GdmCl where it has an end-
to-end distance of 2.80 nm versus 3.72 nm in 6M GdmCl, suggesting even with repulsive 
electrostatic interactions, there are still other attractive interactions present in CGRP in 
buffer. 
 
 
Solvent 2r (nm) 
pH 3 2.80 
pH 4.9 2.39 
pH 8 2.10 
6M GdmCl 3.72 
 
Table 5.1. pH dependence of end-to-end distances for CGRP at 20C. 
 
Briefly, a few controls were done to verify that the change in kR observed when changing 
the solvent pH is due to a change in P(r), and that this change is due to the change in 
overall net charge. Since kR also depends on the quenching rate q(r), the bimolecular 
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quenching rates were measured in each solvent condition. These results are not shown in 
this work, but it was found that the solvent pH has very little effect on the quenching rate 
q(r) and do not follow the trend seen in CGRP. In addition, control experiments of CGRP 
with a D3N mutation (chosen because the asparagine at C3 is present in both IAPP and 
βCGRP)14 were performed to check that the change in kR is due to a change in overall net 
charge and not due to other possible direct pH effects (Figure 5.2). As these figures show, 
the values for kR are indistinguishable for CGRP wild-type and CGRP D3N when they 
have the same net charge.  
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Figure 5.2. Reaction limited rates of CGRP and CGRP D3N with same net 
charge. In (A), CGRP pH 3 (red) has the same net charge (+6) and 
reaction limited rate of CGRP D3N at pH 3 (black), similarly in (B), 
CGRP pH 5 (orange) has the same net charge (+5) and reaction limited 
rate as CGRP D3N pH 8 (maroon). 
 
 
 
Estimates of the end-to-end distance of CGRP, from the measured values of kR and 
assuming a simple Gaussian P(r), are shown in Figure 5.3 as a function of pH. As shown 
in the figure, the end-to-end distance increases from 2.10 nm to 2.80 nm when the net 
charge increases from roughly +4 to +6. 
A B 
D3N pH 8  
CGRP pH 5 
CGRP pH 3 
D3N pH 3 
+6 +5 
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Figure 5.3. pH dependence of the equilibrium end-to-end distance 
distribution of CGRP at pH 8 (green), pH 4.9 (orange), pH 3 (red) and 6M 
GdmCl (blue).  
 
 
To determine whether these short end-to-end distances at low net charge are due to 
changes in the local secondary structure of CGRP or due to changes that affect the long 
range, non-local interactions present in CGRP, CD measurements were done for CGRP 
wild-type at pH 7 (+4 net charge) and compared to those at pH 3 (+6 net charge). For 
practical reasons, the D3N mutant was used for the latter although comparison with wild-
type showed no change (not shown). 
pH 8 (+4) 
  pH 4.9 (+5) 
    pH 3 (+6) 
6M GdmCl 
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Figure 5.4. CD spectra of the pH dependence of CGRP. The CD spectra of 
CGRP pH 7 (green) overlaps with CGRP D3N pH 3 (maroon), despite 
having different end-to-end distances.  
 
 
Figure 5.4 shows that the secondary structure of CGRP does not change when the net 
charge changes. This is consistent with previous CD measurements which found that 
CGRP exhibits no pH dependence in the far UV, which reports on secondary structure, 
but observed a small change in the near UV, which was attributed to increased solvent 
exposure of the cystine as the histidine was titrated.15 This agrees with our experimental 
evidence that CGRP populates larger end-to-end distances as the net charge increases, 
and that this expansion is due to non-local contact formation rather than to changes in 
secondary structure.  
 
 
CGRP pH 7 (+4) 
D3N pH 3 (+6) 
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5.3.2. COMPACTION DUE TO CHARGE SCREENING SCALES WITH DEBYE 
LENGTH 
 
In order to quantify the effect of electrostatic interactions on the end-to-end distance of 
CGRP and check whether the results in the previous section are due to changes in the net 
charge or specific electrostatic interactions with the histidine and aspartic acid, salt was 
added to the buffer to uniformly screen all six charges on the amino acid side chains. For 
these measurements, TTQ experiments were done in increasing salt (KCl) concentrations 
on the CGRP peptide with the highest net charge: CGRP D3N in pH 3 buffer (+6 net 
charge). The amount of salt screening can be related to the Debye length κ-1, which 
depends on the ionic strength of the solution I, as shown in Eq 1 below.  
 
IeN
Tk
A
Br
2
01
2
εε
κ =−       Eq 1 
 
As salt is added and the ionic strength of the solution increases, the Debye length 
becomes shorter meaning that charges are more effectively screened. By measuring 
CGRP by TTQ as a function salt concentration we monitor how salt screening changes 
the observed rate of quenching.  
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Figure 5.5. Plot of the inverse of the observed rate of CGRP D3N at pH 3 
(red circles) as a function of KCl concentration, overlaid upon a plot of the 
Debye length of the solvent (black trianges) as a function of KCl 
concentration.  
 
 
Our results showed that as the concentration of KCl increases, kobs becomes larger 
indicating as the charges on the chain are screened CGRP becomes more compact. In fact, 
a plot of 1/kobs as a function of KCl concentration overlaid on a plot of the Debye length 
of the solvent as a function of KCl concentration shows a clear correlation between the 
two variables (Figure 5.5).  
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Figure 5.6. Plot of the log of the observed quenching rate of CGRP D3N 
(red circles) as a function of the Debye length of the solvent. The data was 
fit to a linear fit line (black line), from which the electrostatic contribution 
to the free energy difference between the open and closed states of CGRP 
was calculated. 
 
Interestingly, further analysis showed that the log of kobs of CGRP is linearly proportional 
to the Debye length of the solvent, as in Figure 5.6. As the observed quenching rate kobs is 
proportional to the equilibrium rate Keq between the open and closed states of CGRP, the 
electrostatic contribution to the free energy cost of forming a contact ∆GOC* in CGRP is 
related to kobs via Eq 2 below.  
 
RT
G
eqobs
OC
eKk
*∆−
=∝       Eq 2. 
 
More specifically, ∆GOC* is the free energy difference between the two sub-ensembles of 
the equilibrium ensemble where the two sub-ensembles are defined as the following: the 
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closed ensemble, where all configurations of the equilibrium ensemble where √<r2> is 
less than 0.4 nm, and the open ensemble, where all configurations of the equilibrium 
ensemble where √<r2> is greater than 0.4 nm. Since the log of kobs depends linearly on κ-1, 
we now have an expression relating ∆GOC* to the Debye length: 
 
1* −
⋅+=∆ κBART
GOC
     Eq 3 
 
where B = 13.68 is the slope and A =  -0.773 nm-1 is the intercept in Figure 5.6 above.  
 
 
5.3.3. SCREENING OF ELECTROSTATIC INTERACTIONS CAUSE COMPACTION 
IN CGRP 
 
In the previous section, a change in kobs when adding salt was attributed to compaction of 
CGRP. However to determine whether the increase in the observed quenching rate with 
the addition of salt to the buffer is due to chain compaction or faster intra-chain diffusion, 
viscosity dependent measurements were done in 500mM KCl.  
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Figure 5.7. Reaction limited rates of (A) CGRP pH 4.9 in 6M GdmCl 
(closed blue circles), buffer (orange circles) and 500mM KCl (closed grey 
circles), and (B) CGRP D3N pH 3 in 6M GdmCl (open blue circles), 
buffer (black circles) and 500mM KCl (open grey circles).  
 
 
Figure 5.7 shows kR of CGRP wt and CGRP D3N in both buffer and 500mM KCl, which 
increase in 500mM KCl relative to buffer for both variants, with shorter end-to-end 
distances in salt consistent with screening of electrostatic interactions. A Gaussian P(r) 
A 
B 
500mM KCl 
      CGRP pH 4.9 (+5) 
6M GdmCl 
 
500mM KCl 
      D3N pH 3 (+6) 
6M GdmCl 
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was used to model these changes in kR and a significant decrease in the end-to-end 
distances from 2.39 nm to 2.19 nm for CGRP wt and 2.83 nm to 2.25 nm for CGRP D3N 
were seen when salt was added (Table 5.2)   
 
 
Peptide Solvent 2r (nm) 
pH 4.9 2.39 
CGRP 
500mM KCl 2.19 
pH 3 2.83 
CGRP D3N 
500mM KCl 2.25 
 
 
Table 5.2 End-to-end distances of CGRP and CGRP D3N in buffer and 
500mM KCl 
 
 
As a visualization of how much these end-to-end distances change in 500mM KCl 
relative to buffer, a plot of the Gaussian P(r) for CGRP D3N with and without 500mM 
KCl shows significant compaction of CGRP D3N in salt (Figure 5.8). From these 
viscosity dependent measurements, we know that the changes in the observed quenching 
rates measured in Figures 5.5 & 5.6 above are reflected by changes in the end-to-end 
distance of CGRP and are due to screening of electrostatic interactions in CGRP. 
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Figure 5.8. Equilibrium end-to-end distance distribution of CGRP D3N 
pH 3 in buffer (black) and 500mM KCl (grey) for a Gaussian chain.  
 
 
5.3.4. A CLOSER COMPARISON BETWEEN CGRP AND IAPP, CONSIDERING 
THE EFFECT OF CHARGES  
 
So far, this chapter has explored the effect of electrostatic interactions on the structure of 
CGRP with increasing net charge causing expansion of CGRP, while the previous 
chapter briefly discussed the differences in structure between CGRP and IAPP, where 
CGRP was more expanded than IAPP in the same solution conditions. Here, we compare 
CGRP and IAPP with the same net charge to see if electrostatic interactions account for 
the observed differences in end-to-end distance in Ct family peptides.  
500mM KCl 
      D3N pH 3 (+6) 
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Figure 5.9. Reaction limited rates for CGRP in 6M GdmCl (closed blue 
circles), pH 4.9 buffer (orange circles) and pH 8 buffer (closed green 
circles), and IAPP in 6M GdmCl (open blue circles) and pH 4.9 buffer 
(open green circles).  
 
 
As Figure 5.9 shows, when CGRP and IAPP have the same net charge of +4, their 
reaction limited rates become very similar with both populating very compact states. The 
Gaussian end-to-end distance distributions (Figure 5.10) show that CGRP and IAPP with 
the same net charge have virtually the same end-to-end distance of about 2.1 nm. This 
suggests that for these peptides, electrostatic interactions are the main contribution to the 
observed differences in end-to-end distance.  
IAPP (+4)   - ○ 
CGRP (+5) - ● 
            (+4) - ●  
IAPP   - ○ 
CGRP - ● 
6M GdmCl 
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Figure 5.10. Equilibrium end-to-end distance distribution for CGRP in 6M 
GdmCl (solid blue line), pH 4.9 buffer (orange line) and pH 8 buffer (solid 
green line), and IAPP in 6M GdmCl (dashed blue line) and pH 4.9 buffer 
(dashed green line) for a Gaussian chain. 
 
 
5.4. DENATURANT EXPANSION VERSUS CHARGE SCREENING IN CGRP 
 
5.4.1. COLLAPSE DUE TO CHARGE SCREENING SEEN IN GDMCL BUT NOT 
UREA 
 
So far we have seen that electrostatic interactions modulate the structure of CGRP, 
however as Figure 5.1 shows, CGRP with a high + 6 net charge still has a shorter end-to-
end distance than in 6M GdmCl. The denaturant binding of GdmCl to CGRP must be 
stronger than other attractive intra-chain interactions present in CGRP with a +6 net 
charge. GdmCl and Urea were titrated to see how denaturant binding affects the end-to-
end contact formation rates of CGRP.  
IAPP, CGRP (+4) 
  CGRP (+5) 
CGRP, IAPP 
6M GdmCl 
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First, we looked at CGRP and CGRP D3N in 6M GdmCl and 8M Urea to explore how 
the end-to-end distance changes when the peptide is fully denatured. As Figure 5.11 
shows, 6M GdmCl and 8M Urea “fully” denatures CGRP, with very similar, but smaller 
kR values in all experimental conditions. This makes sense, as in 6M GdmCl and 8M 
Urea the denaturant will have broken all attractive intra-chain interactions through 
preferential binding of the denaturant with the peptide. 
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Figure 5.11. Reaction limited rates of CGRP variants in denaturant: CGRP 
wt in 6M GdmCl pH 4.9 (closed blue circles), CGRP wt in 8M Urea pH 8 
(closed maroon circles), CGRP D3N in 6M GdmCl pH 3 (open blue 
circles), CGRP D3N in 8M Urea pH 3 (open maroon circles).  
 
 
Next, the concentrations of GdmCl and Urea in the solution were titrated to explore the 
effect of increasing denaturant binding on the end-to-end distances of CGRP. In order to 
quantify the effect that changing the GdmCl and Urea concentrations have on the 
structure of CGRP, the radius of gyration was calculated from kobs of quenching as 
described in Appendix III.  The experimental results in Figure 5.12 below show how the 
radius of gyration of CGRP at 10C changes as a function of denaturant concentration. 
Urea 
   CGRP (+4) - ● 
   D3N (+6) - ○ 
6M GdmCl 
   CGRP - ● 
   D3N - ○ 
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Figure 5.12. The radius of gyration of CGRP variants as a function of 
denaturant concentration. A. CGRP wild-type in GdmCl pH 7 (blue circles) 
and Urea pH 8 (red triangles), B. CGRP D3N pH 3 in GdmCl (blue 
circles), Urea (red triangles), and KCl (green arrows).  
 
 
In all cases, the radius of gyration increases as the concentration of denaturant increases. 
However, while the radius of gyration of CGRP with a +4 net charge increases 
monotonically in GdmCl and Urea, the radius of gyration of CGRP D3N with a +6 net 
charge decreases at low GdmCl concentrations (but increases monotonically in Urea). 
A 
B 
Urea 
GdmCl 
CGRP pH 7 & 8 (+4) 
Urea 
GdmCl 
D3N pH 3 (+6) 
KCl 
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According to Figure 5.12, the turnover point at which the concentration of GdmCl where 
the denaturant binding effect starts to take over charge screening occurs at around 
500mM GdmCl at 10C. It is surprising that such a relatively small change in net charge 
has a dramatic effect on the charge screening effect in GdmCl. To further explore this, we 
used polymer models to fit the data. 
 
5.4.2. CHARGE POSITION NEEDS TO BE TAKEN INTO ACCOUNT 
 
The discovery that a +2 difference in net charge is sufficient to change the behavior of 
CGRP in GdmCl was surprising as compared to other IDPs, CGRP has a low net charge 
per residue (Figure 2.4) and a +2 difference in net charge is relatively small. Previous 
studies noted that this compaction at low GdmCl concentrations only occurred in IDPs 
that were charge balanced9 and a similar study on a unfolded protein where the net charge 
went from -4 to +10 by changing the solvent pH always collapsed at low GdmCl 
concentrations.10 To understand why a +2 net charge difference in CGRP can change the 
way it behaves in denaturant, a collaboration was established with Andrea Soranno from 
the University of Zurich. A. Soranno first fit the experimental data on CGRP from Figure 
5.12 to a polyampholyte model which has successfully been used to model the 
dimensions of the disordered proteins, prothymosin α and the N-terminal domain of HIV-
1 integrase,9,10,16 with CGRP having N = 37 monomers of length b = 0.36 nm. This model 
is based on the original model by Higgs and Joanny16 with the electrostatic contribution 
to the radius of gyration is modeled using Eq 4.  
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where the effective excluded volume ν*b3 in Eq 5 has an electrostatic contribution νelb3 
such that 
 
33
0
3
* bbb elννν +=
     
 Eq 6 
 
The polyampholyte model is given by: 
 
νel
PA
=
4pilb ( f − g)2
κ(I)2b3 −
pilb
2( f + g)2
κ(I)b3
    
Eq 7
 
 
where lb is the Bjerrum length, I is the ionic strength of the solvent, and f and g are the 
positive and negative fractions of the chain, respectively.16 In polyampholyte theory, the 
first term in Eq 7 is the contribution of electrostatic repulsion to the excluded volume, 
while the second term is the electrostatic attraction contribution to the excluded volume 
of the polymer chain. As CGRP is a relatively short protein and is a weak polyampholyte 
(and in the case of CGRP D3N, a polyelectrolyte only), this model overestimated the 
contribution of electrostatic interactions to the compaction of CGRP so, the data were 
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then fit with a polyelectrolyte model,17 which eliminates the contribution of electrostatic 
attraction of oppositely charged amino acids. 
 
νel
PE
=
4pilb ( f − g)2
κ(I)2b3       Eq 8 
 
The polyelectrolyte contribution Eq 8 to the excluded volume estimation of CGRP also 
overestimates the compaction at low GdmCl concentrations.  
 
 
 
Figure 5.13. Sequence of CGRP variants with positive (red) and negative 
(blue) charges highlighted. (A) CGRP wild-type at pH 8, (B) CGRP D3N 
at pH 3.  
 
A 
B 
CGRP pH 8 (+4) 
D3N pH 3 (+6) 
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A close look at the position of the charges in the sequences of CGRP and CGRP D3N 
reveal some subtle differences (Figure 5.13). Besides a difference in the overall net 
charge, the differences (including a plus/minus charge attraction) between the two 
variants are limited to the N-terminal region, suggesting that CGRP might be sensitive to 
the type and position of the charges in the sequence. To model the position of the charges, 
A. Soranno used a simple Gaussian model that explicitly calculates the electrostatic 
contribution to the excluded volume by taking into account the relative distance between 
charges along the chain,13 seen in Eq 9 below.   
 
νel =
lb
Nb3
c ic j
i − j 0.5αb e
−κ (I ) i− j 0.5αb
i, j
∑
    Eq 9 
 
In Eq 9, i and j are the position of the charged residues, with ci and cj being the charge on 
those residues based on the pKa of the amino acids and the solvent conditions. To take 
into account the expansion of CGRP due to denaturant binding, the charge screening is 
modeled in conjunction with a Schellman denaturant binding model9,18 given in Eq 10 
below: 
 
 





+
+=
Ka
KabNRG 1
15.0 ρα
     Eq 10 
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where ρ is the denaturant expansion coefficient, K is the denaturant binding constant, and 
a is the activity of the denaturant. This combined model takes into account charge 
screening at low GdmCl concentrations and denaturant binding and expansion at higher 
denaturant concentrations. For CGRP, the radius of gyration is rescaled to: 
 
Rg (I,ρ,K,a) = α(I,ν )
n0.5b
60.5
1+ ρ Ka
1+ Ka
 
 
 
 
 
    Eq 11 
 
Experimental data for CGRP at +4 and CGRP D3N at +6 were successfully fit to Eq 9 
and 11 above. The fits for CGRP and CGRP D3N are shown in Figure 5.14.  
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Figure 5.14. The radius of gyration of CGRP variants as a function of 
denaturant concentration. A. CGRP wild-type in GdmCl pH 7 (blue circles) 
and Urea pH 8 (red triangles), B. CGRP D3N in GdmCl pH 3 (blue 
circles), Urea pH 3 (red triangles), and KCl pH 3 (green arrows). The 
black lines are the fit from the charge patterning model described in Eq 11.   
 
 
From these fits, we now have values for the excluded volume term with the electrostatic 
contribution and the denaturant binding term, given in Table 5.3 below. 
 
A 
B 
Urea 
GdmCl 
CGRP pH 7 & 8 (+4) 
Urea 
GdmCl 
D3N pH 3 (+6) 
KCl 
denaturant binding 
model 
denaturant binding  
charge screening  
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Net Charge Solvent Ν K ρ 
GdmCl 0.04 ± 0.03 1.6 ± 0.1 
+6 
(pH 3) Urea 
0.00 ± 0.06 
0.01 ± 0.02 6 ± 10 
GdmCl 0.20 ± 0.04 0.16 ± 0.07 1.6 ± 0.4 
+4 
(pH 7 & 8) Urea 0.09 ± 0.06 0.04 ± 0.03 4 ± 2 
 
 
Table 5.3 Fitting parameters for fits for CGRP titration. For CGRP with a 
+6 or +4 net charge in GdmCl and Urea, the parameters ar: ν - excluded 
volume of CGRP, ρ - denaturant expansion coefficient, K - denaturant 
binding constant. 
 
 
As expected, GdmCl binds more efficiently than Urea and the electrostatic contribution 
to the excluded volume is small for these peptides compared to other disordered proteins. 
This suggests that CGRP cannot be characterized as a “simple” polyampholyte or 
polyelectrolyte, but instead the position of the charges and the types of charge 
interactions must be taken into account. However, through the modification of a 
polyampholyte polymer model to take into account the position of the charges, we can 
quantitatively account for the data, extracting effective denaturant binding constants and 
effective excluded volumes for CGRP. Specifically in the case of CGRP, the single N3 
charge has a dramatic effect on the structure of CGRP, due to its specific location along 
the sequence, which suggests a possible functional role for this charge.  
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5.4.3. SECONDARY STRUCTURE IS NOT AFFECTED BY ELECTROSTATICS 
 
To determine whether the decrease in the radius of gyration at low GdmCl concentrations 
is due to changes in non-local interactions or secondary structure at low GdmCl 
concentrations, CD measurements titrating GdmCl were performed on CGRP wild type at 
pH 7 and CGRP D3N at pH 3. The CD minima at 222 nm was measured and plotted as a 
function of GdmCl concentration with the minima at 222 nm corresponds to the amount 
of secondary structure in CGRP.  
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Figure 5.15. GdmCl titration of the CD signal at 222 nm of CGRP variants. 
The CD  of CGRP wild-type in pH 7 buffer (open green circles) and 
CGRP D3N in pH 3 buffer (closed maroon circles) were measured as a 
function of GdmCl concentration, and the signal at 222nm, which reports 
on the secondary structure, decreases monotonically.  
 
 
CGRP pH 7 (+4) 
D3N pH 3 (+6) 
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As Figure 5.15 shows, the CD signal at 222 nm for both peptides decrease in a monotonic 
way, consistent with the loss of secondary structure in disordered proteins. Therefore, the 
compaction in CGRP D3N at low GdmCl concentrations are due to non-local interactions 
that directly affect the end-to-end distances of CGRP and its variants.  
 
5.5. DISCUSSION 
 
In this chapter, we explored the effect of electrostatic interactions on CGRP. Unlike 
previous reports on secondary structure of CGRP15 we found that the end-to-end distance 
(a non-local property) is highly sensitive to electrostatic interactions between charged 
residues in the sequence. This emphasized the importance of measuring non-local 
(tertiary) structural properties of IDPs in addition to local (secondary) structural 
properties. Screening the charges with salt caused CGRP to populate compact states, with 
this compaction depending linearly on the Debye length of the solution. When exploring 
this charge screening effect by measurements of the end-to-end contact formation rates of 
CGRP in an ionic denaturant (GdmCl), it was found that with a +6 net charge, CGRP will 
compact at low ionic concentrations before the denaturant effect takes over. As discussed 
in Chapter One these findings are relevant to current studies on the effect of electrostatic 
interactions on the structure of IDPs.  As described in that chapter, the structure of the 
disordered unbound state of IDPs is expected to affect the both the affinity and the 
kinetics of binding to receptors, and therefore their biological function. 
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Moreover, these findings are directly relevant to current models on the mechanism by 
which CGRP is responsible for the transmission of pain signals and triggering migraines. 
As discussed in Chapter Two, CGRP is known for its vasodilatory effects and role in the 
transmission of pain in the body. The release of CGRP in sensory neurons triggers a 
vasodilatory response which provides a cardiac protective effect and reduces ischemia 
and other inflammation19,20 and there is a significant body of evidence that the release of 
CGRP is triggered by a drop in the extracellular pH, either through the release of protons 
via anaerobic respiration or the release of lactic acid during cell damage.20 Multiple 
experiments have found an increase in CGRP levels or an increase in CGRP 
immunoreactivity when lowering the pH of the medium or with the addition of calcium 
or proton ions.21-24 This suggests that the mechanism that triggers the release of CGRP, 
thereby providing a cardioprotective vasodilatory response, is the lowered pH of the 
extracellular medium due to cell damage.  
 
Low extracellular pH is even suspected to play a role in the transmission of pain in the 
body via the release of CGRP. Cancer cells actually cause significant sprouting of CGRP-
producing sensory nerve fibers nearby25,26 while other studies have found that cancer cells 
have a reverse pH gradient, with lower extracellular pH.26 As mentioned in Chapter Two, 
CGRP plays an important role in back pain, and there is a new theory that the genesis of 
back pain is due to the low pH in the intervertebral disks due to high levels of lactate in 
the disks from inflammation.27 As the release of CGRP and activation of the CGRP 
receptor is sensitive to acidic conditions in the body, the experimental evidence presented 
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in this work showing CGRP’s structural sensitivity to solution pH suggests that the 
binding of CGRP to its receptor is sensitive to variations in the structure of CGRP. 
In short, there is a significant body of evidence that lowering the pH of the extracellular 
medium triggers the release of CGRP, thereby transmitting pain or prompting a 
vasodilatory response.  
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CHAPTER 6 
EVIDENCE FOR INTERNAL FRICTION IN CGRP 
 
6.1. INTRODUCTION TO INTERNAL FRICTION 
 
Experimental measurements of the internal dynamics of disordered proteins are of 
interest in the IDP field as there is a significant body of evidence that the dynamics of the 
monomer state is important for biological function. As discussed in Chapter One, it is 
thought that the dynamics of disordered proteins can affect the binding rates and the 
function of these proteins.1-4 Recently, research has started to focus on “internal friction” 
or the roughness of the diffusional energy landscape.5-7 The reconfiguration time of 
unfolded or disordered proteins have been found to depend on two effects: “wet” or 
solvent mediated friction (in which the friction is proportional to the viscosity of the 
solution), and “dry” or solvent viscosity independent friction (in which the dynamics are 
mediated by interactions within the protein itself).8-9 Internal friction, or “dry” solvent 
independent friction, has been found to have an additive effect on the chain 
reconfiguration time.8 
 
As the internal friction of disordered proteins can have a significant effect on the 
dynamics of the proteins, recent studies have focused identifying sources of internal 
friction. Previous FRET measurements on disordered proteins found that in low 
denaturant concentrations, solvent-independent (or “dry”) internal friction is greater when 
the protein populates shorter end-to-end distances, which was attributed to a greater 
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number of steric clashes slowing down the reconfiguration time of compact proteins.8 As 
the solvent concentration increases, the internal friction contribution to the 
reconfiguration time decreases such that when the protein is fully denatured, only “wet” 
friction contributes to the reconfiguration time.8 This is consistent with previous studies 
that showed a correlation between the dimensions of unfolded proteins and changes to 
their chain dynamics.10-11 Simulations on internal friction in unfolded proteins have also 
shown that despite the presence of non-local interactions which can form “kinetic traps,” 
instead it is concerted dihedral rotations in collapsed states of IDPs that a play a 
significant role in internal friction, slowing down the dynamics of IDPs.9  Aside from 
these studies, there is currently little experimental evidence for internal friction in 
disordered proteins.  
 
To measure the internal dynamics of CGRP, we look at the diffusion limited rates 
corrected for solvent viscosity (ηkD+) measured by TTQ, which report on the time it takes 
to form a contact between the tryptophan and the cystine. Because the diffusion limited 
rate depends on both the intra-chain diffusion coefficient, D and the end-to-end distance 
distribution P(r), for a simple analysis of the dynamics of two proteins, they must have 
the same end-to-end distance so that any differences in the diffusion limited rate is due to 
intra-chain dynamics rather than a change in the structure of CGRP. Because of this, we 
must compare both kR, which depends only on P(r) and ηkD+ in order to elucidate the 
dynamics of CGRP in solution. In this chapter, we will focus on the internal dynamics of 
CGRP and identifying possible sources for internal friction that might affect the 
reconfiguration time of CGRP in solution. 
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6.2. EXPERIMENTAL METHODS 
 
The experimental methods were described previously in Chapters Four and Five. 
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Figure 6.1. Reaction limited (A) and diffusion limited (B) rates of CGRP 
pH 4.9 in 6M GdmCl (blue) and buffer (orange).  
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The two graphs in Figure 6.1 above are the reaction and diffusion limited rates of CGRP 
in both buffer at pH 4.9 and 6M GdmCl. As discussed in Chapter 4, CGRP has shorter 
end-to-end distances in buffer, with kR increasing three-fold in buffer compared to 
denaturant. However, when looking at ηkD+, CGRP now has very similar rates in both 
buffer and denaturant. As CGRP is significantly more compact in buffer than in GdmCl, 
the similar ηkD+ must be accounted for by CGRP having slower dynamics in buffer 
compared to denaturant. Intuitively this makes sense because in buffer CGRP will have 
attractive non-local intra-chain interactions that are “sticky,” slowing down the 
reconfiguration time compared to CGRP in denaturant, in which CGRP will have only 
excluded volume interactions. 
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Figure 6.2. Reaction limited (A) and diffusion limited (B) rates of CGRP 
in 6M GdmCl (blue), pH 3 (red), pH 4.9 (orange) and pH 8 (green).  
 
 
As reported in Chapter Five, electrostatic interactions strongly modulate the structure of 
CGRP, with kR increasing as the net charge on CGRP decreases. However, the pH 
dependence of the diffusion limited rates stays relatively constant as the net charge on 
CGRP changes (Figure 6.2), suggesting that as the net charge on CGRP decreases, the 
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internal dynamics slow down: CGRP with a “high” net charge of +6 has slightly faster 
dynamics than CGRP with a “low” net charge of +4. Thus the pH dependence of CGRP’s 
dynamics follows the same trend observed in buffer versus denaturant, where the 
reconfiguration time depends on the net charge of the chain due to “sticky” electrostatic 
interactions that slow down the internal dynamics of CGRP. 
 
As Figures 6.1 and 6.2 just showed, attractive intra-chain interactions, including 
electrostatic interactions, slow down the intra-chain dynamics of CGRP. To further 
explore the role of electrostatic interactions on the internal dynamics of CGRP, 
electrostatic interactions were screened by the addition of 500mM KCl. Figure 6.3 below 
shows both kR and ηkD+ of CGRP (pH 5, with a net charge of +5) in buffer and salt, and 
Figure 6.4 shows CGRP D3N (pH 3, with a net charge of +6) in the same conditions. As 
discussed in Chapter Five, kR of both CGRP variants in 500mM KCl are faster than in 
buffer, with the screening of charges causing compaction in CGRP. On the other hand, as 
Figures 6.3 and 6.4 show, ηkD+ are now significantly faster at 500mM KCl than at 0M 
KCl. This means that despite CGRP populating collapsed states in high salt compared to 
at 0M KCl, the intra-chain dynamics speed up. This is surprising because previously 
published experimental and theoretical evidence has shown that compact states increase 
internal friction and slow down dynamics, rather than speed them up.8,9 This suggests that 
at least for CGRP, electrostatic interactions are a primary contributor to internal friction, 
and elimination of these interactions speed up the internal dynamics.  
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Figure 6.3. Reaction limited (A) and diffusion limited (B) rates of CGRP 
wild type in 6M GdmCl (closed blue circles), pH 4.9 (orange), and 
500mM KCl (closed grey circles).  
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Figure 6.4. Reaction limited (A) and diffusion limited (B) rates of CGRP 
D3N in 6M GdmCl (open blue circles), pH 3 (black), and 500mM KCl 
(open grey circles).  
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6.4. INTERNAL FRICTION IN CT FAMILY PEPTIDES 
 
This chapter has explored how the internal dynamics of CGRP are modulated by 
electrostatic interactions, with non-local interactions slowing down the dynamics of 
CGRP relative to GdmCl. Now we can compare the diffusion limited rates for CGRP and 
IAPP and see how the internal dynamics differ among Ct family peptides. In Figure 6.5, 
kR and ηkD+ for CGRP at pH 8 and IAPP at pH 4.9 in buffer and denaturant are shown. 
As discussed in Chapter Five, when CGRP and IAPP have the same net charge as they do 
here, they have similar kR and very similar end-to-end distances. However, a look at ηkD+ 
shows that IAPP has significantly faster dynamics than CGRP, despite being equally 
compact as CGRP. This suggests that unlike CGRP, IAPP has few “sticky” intra-chain 
interactions which would slow down its dynamics in buffer and that even when 
populating very compact states, IAPP has relatively little internal friction.  
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Figure 6.5. Reaction limited (A) and diffusion limited (B) rates of CGRP 
in 6M GdmCl (closed blue circles), pH 4.9 (orange), and pH 8 (closed 
green circles) and IAPP in 6M GdmCl (open blue circles) and pH 4.9 
buffer (open green circles).  
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6.5. DISCUSSION 
 
 By measuring the diffusion limited rate of CGRP using tryptophan triplet quenching, we 
were able to determine how the presence of non-local interactions such as electrostatics 
affect the reconfiguration time. This chapter showed that CGRP has greater internal 
friction in buffer compared to denaturant due to the presence of attractive interactions 
present in buffer, while decreasing the net charge of CGRP in buffer appears to slow 
down CGRP’s internal dynamics, suggesting that electrostatic interactions contribute to 
internal friction and slow down the intra-chain diffusion. Surprisingly however, even 
when CGRP and IAPP have the same net charge and they both populate compact states 
with the same end-to-end distance, internal friction is greater in CGRP than IAPP. 
 
The results on CGRP discussed in this chapter are some of the first results showing 
experimental evidence that electrostatic interactions contribute to internal friction in IDPs. 
Here we show that non-local electrostatic interactions such as Coulomb interactions 
contribute to viscosity-independent internal friction in CGRP. Similarly IAPP has faster 
dynamics than CGRP despite having the same net charge and same end-to-end distance. 
As IAPP aggregates into amyloid fibrils while CGRP does not, this might contribute to 
IAPP’s aggregation propensity, with the faster dynamics seen in IAPP allowing it to 
sample transient states quickly compared to CGRP which has “trapped” states slowing 
down its dynamics. Conversely, as electrostatic interactions slow down the dynamics of 
CGRP significantly, this suggests that attractive electrostatic interactions between CGRP 
and its receptor might help CGRP increase its binding rate through attractive inter-
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molecule interactions. In agreement with previous literature, at low pH, CGRP is also 
more expanded with correspondingly faster dynamics, meaning that CGRP quickly goes 
through its ensemble of conformations which can significantly affect the binding kinetics 
between CGRP and its receptor. The experimental results presented in this chapter 
suggest that electrostatic interactions play a significant role in not only the structure of 
the monomeric state of CGRP, but also its internal dynamics. 
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CHAPTER 7 
CONCLUSIONS 
 
The characterization of the non-local structural and dynamical properties of the CGRP 
monomer in solution was the focus of this work. The unbound, free state of CGRP was 
measured using a nanosecond laser-pump spectrophotometer, by which the end-to-end 
distance (a structural property) and the rate of end-to-end contact formation (intra-chain 
diffusional dynamics) was measured. Using this technique, it was revealed that CGRP 
adopts very compact states in buffer relative to denaturant, populating states with very 
short end-to-end distances. Our findings also show that the disulfide loop (N_loop) found 
at the N-terminus of CGRP is partly responsible for some of this collapse, similar to the 
mechanism seen in IAPP.1 However, CGRP does not become as compact as a similar 
peptide IAPP, despite sharing 47% sequence homology,2,3 therefore the observed 
differences between the structure (or degree of compaction) of CGRP and IAPP are 
modulated by differences in the sequence.  
 
While previous reports on the secondary structure of CGRP found little pH dependence4 
we found that electrostatic interactions between charged residues in the sequence appear 
to modulate compaction in CGRP. When titrating charged residues by changing the 
solvent pH, we found that the end-to-end distance of CGRP is sensitive to the net charge 
on the chain and the observed differences in the structure of CGRP and IAPP can be 
accounted for by differences in net charge. In addition, uniformly screening the charges 
by the addition of salt allow CGRP to populate compact states, with this compaction 
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depending linearly on the Debye length of the solution. We also found that in ionic 
denaturant, there is an interplay between charge screening and denaturant expansion, with 
charge patterning determining how the radius of gyration of CGRP changes with 
denaturant concentration. 
 
Finally, through measurements of the rate of end-to-end contact formation in CGRP, this 
work presents the first experimental evidence of internal friction in Ct family peptides. 
We show that CGRP has greater internal friction in buffer compared to denaturant, with  
attractive intra-chain interactions present in buffer slowing down the diffusional 
dynamics of CGRP. It was also found that decreasing the net charge of CGRP in buffer 
appears to slow down CGRP’s internal dynamics, suggesting that electrostatic 
interactions contribute to internal friction. Surprisingly however, CGRP was found to 
have slower intra-chain diffusion than IAPP in buffer, but not in denaturant, even when 
they both populate compact states with the same end-to-end distance, suggesting that 
internal friction is greater in CGRP than IAPP. 
 
The results of this work show that for CGRP, electrostatic interactions play an important 
role in both the structure and dynamics of CGRP. As discussed in Chapter One, the 
structure and dynamics of disordered proteins is thought to play an important role in the 
thermodynamics and kinetics of receptor binding and activation. Therefore, the results of 
this work suggest that electrostatic interactions might help CGRP modulate its binding 
rate to the CGRP receptor through attractive inter-molecule interactions between CGRP 
and its receptor. Electrostatic interactions also affect the speed which CGRP goes through 
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the ensemble of conformations, which can significantly affect the binding kinetics 
between CGRP and its receptor. As the release of CGRP and activation of the CGRP 
receptor is sensitive to acidic conditions in the body,5-8 the experimental evidence 
presented in this work showing CGRP’s sensitivity to electrostatic interactions suggests a 
potential mechanism for the modulation of the binding of CGRP to its receptor. 
 
In addition, this work compares CGRP with IAPP, a Ct family member with high 
sequence homology, expanding upon previous work done by Vaiana group members.1 
This work explored sequence specific effects that affect the structure and dynamics of 
CGRP and IAPP, including electrostatic interactions and intra-chain interactions 
modulated by the N_loop. In the last few years migraine research has shifted focus to 
disrupting the CGRP-receptor pathway through the design of pharmacological drugs that 
bind to either CGRP or its receptor, inhibiting receptor activation and therefore 
preventing or reducing the frequency of migraine attacks.9 Therefore, it is important to 
design therapeutics that are able to selectively target CGRP and its receptor only, and not 
other, similar Ct family members. By comparing CGRP and IAPP, the results of this 
work help understand what types of non-local interactions affect the binding affinities of 
Ct family peptides and will allow better and more precise drug engineering. 
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APPENDIX I  
VISCOSITY DEPENDENCE OF kobs OF CGRP 
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The observed quenching rate was measured as a function of temperature and solution 
viscosity to extract the reaction and diffusion limited rates for analysis of the structure 
and dynamics of CGRP. The figures below are the plots of the viscosity dependence of 
CGRP in the solution conditions discussed in this work.  
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Figure A.1. Viscosity dependence of kobs for CGRP and D3N. The inverse 
of kobs is plotted as a function of solution viscosity for: CGRP in (A) pH 3, 
(B) pH 4.9, and (C) pH 8 buffers and (D) 6M GdmCl, (E) 8M Urea and (F) 
500mM KCl and D3N in (G) pH 3, (H) pH 4.9, and (I) pH 8 buffers and 
(J), 6M GdmCl, (K) 8M Urea and (L) 500mM KCl.  
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APPENDIX II 
DETERMINING THE VISCOSITY OF SOLUTIONS 
  140 
In order to separate the reaction limited and diffusion limited rates, accurate values for 
the viscosity of the sucrose solutions were needed. Dynamic light scattering (DLS) 
experiments were performed to verify the viscosity of the sucrose solutions in both 
aqueous solution and 8M Urea. DLS measures the intensity fluctuations of scattered light 
over time, with bigger particles diffusing through the solution slower and therefore 
having slower intensity fluctuations (and vice versa). These intensity fluctuations are time 
correlated, and in monodisperse samples the second order autocorrelation function 
corresponds to a single exponential decay, Γ which is given by the expression 
 
)2exp(),()2( ττ Γ−+= ABqg      Eq 1 
 
where q is the wave vector, and τ is the delay time. The wave vector q is expressed by 
 
( )2sin4 0 θλ
pin
q =       Eq 2 
 
where n0 is the index of refraction, λ is the wavelength of the laser beam (λ = 622 nm) 
and θ is the scattering angle (90o). The decay of the autocorrelation function, Γ is related 
to the diffusion of the particles in solution via the diffusion coefficient, D. 
 
Dq 2=Γ        Eq 3 
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The diffusion of particles in solution is characterized by the Stokes-Einstein relation, 
which relates the diffusion coefficient to the hydrodynamic radius rh of the particles. 
  
h
B
r
Tk
D
piη6
=        Eq 4 
   
As apparent in Eq 4, the diffusion of the particles in solution also depends on the solvent 
viscosity η and temperature T. As the only variable that will change with each solution 
besides η is the index of refraction n0, this was empirically measured to correct for the 
change in the index of refraction as sucrose is added. 
 
Polystyrene spheres with a radius of 73.5 +/- 1 nm in a 1% suspension from Duke 
Scientific were used as the control in these experiments. The spheres were carefully 
sonicated to ensure monodispersity. The sucrose buffer were filtered with a Whatman 
0.02 um filter and polystyrene spheres were added to create a 0.01% solution of spheres 
in buffer.  DLS temperature scans were performed on these solutions by taking 200 
correlation functions at each temperature used in TTQ experiments, after waiting 40-60 
minutes for thermal equilibration at each temperature. DLS measurements of the 
diffusion coefficient of polystyrene spheres in sucrose solutions were measured using a 
Wyatt DynaPro NanoStar. The diffusion coefficient D was calculated from the data by 
Dynamics software v 7.2 (Wyatt). D was substituted into the Stokes-Einstein equation 
above, using the radius of the spheres as the rH of particles in solution, thereby giving 
accurate values of the viscosity of the solutions used for TTQ experiments.  
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APPENDIX III  
CALCULATION OF kR AND rG FROM kobs 
  143 
TTQ experiments involving the titration of GdmCl, Urea, and KCl were performed to 
explore the effect of the addition of denaturant on the structure of CGRP. Thherefore it is 
important to determine how the radius of gyration, which is a structural property, depends 
on the observed quenching rate. It is not feasible to do viscosity dependent measurements 
at each solvent concentration, due to the large amounts of sample and time involved. 
Therefore, only extreme solvent concentrations (0M and 6M GdmCl, 0M and 8M Urea, 
and 0M and 0.5 M KCl) have experimentally determined values for kR from which the 
radius of gyration, assuming a Gaussian chain, is calculated. The radius of gyration of 
CGRP at these intermediate solvent concentrations were calculated as described below. 
 
Using kR from the viscosity dependent analysis and the observed quenching rate kobs from 
the independent fit of CGRP at extreme solvent concentrations, a proportionality constant 
A, was calculated that gives an empirical relationship between the two rates (Eq 1). 
 
R
obs
k
k
A =        Eq 1 
 
There is very little variation in A for all solvent concentrations, so it is assumed that any 
changes in structure, or kR, due to changing solvent are reflected by changes in kobs. A 
linear interpolation of A versus solvent concentration was calculated such that each 
experimental solvent concentration has a characteristic A that reflects an increase in A 
with increasing solvent concentration. Using these characteristic values for A, values for 
kR can now be calculated from each experimental kobs for each solvent concentration.  
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A Matlab program was written to calculate the radius of gyration from a set of 
experimental kobs values by finding an average end-to-end distance for a given kR. The 
code takes the experimental values for kobs at 10C, and multiples this by the value for A 
calculated for that solvent concentration to get a calculated value for kR. To find the end-
to-end distance that gives this value for kR assuming a Gaussian chain, a matrix of end-to-
end distance values from a0 to ½ the contour length is generated, and a second matrix of 
kR values were calculated using these generated values for the end-to-end distance. The 
computer then uses a minimization search to find the theoretical kR closest to the 
experimental value for kR. The end-to-end distance which gave the calculated value for 
kR that most closely matched was then used to find the radius of gyration (Eq 2).  
 
6
2
r
rG =        Eq 2 
 
Using these values of the radius of gyration we can now evaluate how changing solution 
conditions affect the structure of CGRP.  
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APPENDIX IV  
CALCULATION OF QUENCHING OF TRYPTOPHAN BY N_LOOP 
  146 
While previous work has found that free cystines have a similar quenching rate as free 
cysteines,1 the effect the specific geometry of the N_loop on the quenching rate q(r) must 
be accounted for as the geometry of the N_loop might decrease the actual accessible area 
of the cystine. The distance dependence of the quenching rate of tryptophan by cysteine 
is known to be exponential from measurements done in trehalose glass by Lapidus, et al 
2001,2 and takes the form 
 
( ))(exp)( 00 arbqrq −=
     Eq 1 
 
a0 is the van der Waals contact (4 Å), while both q0 (4.2 ns-1) and b (4.0 Å-1) were 
determined experimentally.2 As the quenching rate of the tryptophan in CGRP is still 
assumed to have an exponential distance dependence, a rescaling factor that takes into 
account the geometry of the N_loop was calculated by finding a characteristic q0* which 
is proportional to q0, the quenching coefficient found previously.2 
 
Since CGRP and IAPP have a rigid N_loop between residues 2 & 7, we assume the 
effective polymer length of these peptides is 31 amino acids. We know from previous 
work that a 31mer has an effective end-to-end distance of 3.45 nm in 6MGdmCl, and Rg 
of ~1.4 nm assuming a Gaussian P(r).3 Assuming that hIAPP in denaturant behaves as an 
ideal chain, hIAPP will therefore have an end-to-end distance of 3.45 nm in 6M GdmCl.  
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A MatLab program was written to find the rescaling factor q0* for the bimolecular 
quenching coefficient of CGRP and other Ct family peptides with similar N_loops. The 
program defines kR as a function of two functions, P(r) and q(r), as shown in Eq. 2.  
 
∫=
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a
R drrqrPk
0
)()(       Eq 2 
 
The equation for q(r) used in the MatLab program is given by Eq 1, except now the 
proportionality constant is taken into account:  
  
( )( )000 exp)( arbqqrq −•= ∗      Eq 3 
 
To find q0* for all Ct family peptides that have an N_loop quencher, a table of values was 
created for q0* between 0 and 1 (ranging from no quenching by the N_loop to the N_loop 
having the same quenching rate as a free cysteine) at 0.0001 intervals. Using a Gaussian 
P(r) with an end to end distance of 3.45 nm (corresponding to hIAPP in denaturant) and 
Eq. 3 above, a set of kR values was calculated, one for each value of q0*. Using a 
minimization search, the program finds the rescaling factor q0* that gives a calculated 
value of kR that most closely matches the experimental value for kR of 0.32 µs-1 for 
hIAPP in 6M GdmCl pH 4.9 buffer at 20C (measured in Vaiana, et al 2009).1 This gives 
a rescaling factor q0* for the N_loop of Ct family peptides of 0.1681.  
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PUBLISHED WORK 
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The work in this appendix was published in PLOS One under Tsen, S.-W.D., Kingsley, 
D.H., Kibler, K., Jacobs, B., Sizemore. S., Vaiana, S.M., Anderson, J., Tsen, K.-T., 
Achilefu, S. (2014) Pathogen Reduction in Human Plasma Using an Ultrashort Pulsed 
Laser. PLoS ONE 9(11): e111673. doi:10.1371/journal.pone.0111673. This work was 
done in collaboration with Dr. Kong-Thon Tsen and expanded upon previously published 
work on the inactivation of viruses using ultra-short pulsed lasers. My contribution to this 
work consisted of the measurement and analysis of light scattering and circular dichroism 
measurements of fibrinogen, both before and after irradiation with an ultra-short laser, in 
order to check for any changes in secondary structure or aggregation after irradiation. 
 
ABSTRACT 
 
Pathogen reduction is a viable approach to ensure the continued safety of the blood 
supply against emerging pathogens. However, the currently licensed pathogen reduction 
techniques are ineffective against non-enveloped viruses such as hepatitis A virus, and 
they introduce chemicals with concerns of side effects which prevent their widespread 
use. In this report, we demonstrate the inactivation of both enveloped and non-enveloped 
viruses in human plasma using a novel chemical-free method, a visible ultrashort pulsed 
laser. We found that laser treatment resulted in 2-log, 1-log, and 3-log reductions in 
human immunodeficiency virus, hepatitis A virus, and murine cytomegalovirus in human 
plasma, respectively. Laser-treated plasma showed ≥70% retention for most coagulation 
factors tested. Furthermore, laser treatment did not alter the structure of a model 
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coagulation factor, fibrinogen. Ultrashort pulsed lasers are a promising new method for 
chemical-free, broad-spectrum pathogen reduction in human plasma. 
 
INTRODUCTION 
 
Pathogen reduction (PR) is an ideal strategy to combat emerging pathogens and ensure 
the continued safety of blood products. However, the PR techniques that are currently in 
use for clinical blood products have limitations that preclude their widespread use (for 
reviews, see [1–3]). The solvent-detergent (SD) method,4,5 which inactivates enveloped 
viruses by disrupting lipid membranes, was discontinued in the United States due to an 
association with unexpected thromboses in some patients.4,6 Light-activated 
photochemicals such as methylene blue7,8 and amotosalen,9,10 which inactivate pathogens 
through crosslinking, also involve introducing chemicals with concerns of side effects. 
Such side effects include allergic reactions (in the case of methylene blue) and the 
generation of antibodies against the treated blood product (in the case of the chemical S-
303),1 as well as the concern of unknown, unpredictable long-term effects that invariably 
arise with any administered compound. Furthermore, all of the above mentioned methods 
are ineffective against non-enveloped viruses such as hepatitis A virus (HAV).6 
 
Ultrashort pulsed (USP) lasers have recently emerged as an attractive potential technique 
for pathogen inactivation.11 The visible USP laser PR technology does not involve 
potentially toxic or carcinogenic chemicals. Visible USP lasers are non-ionizing and do 
not covalently modify proteins, thereby reducing concerns of neoantigen formation. 
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Furthermore, USP laser treatment can inactivate a broad spectrum of viruses and 
bacteria,11-14 including non-enveloped viruses that are traditionally difficult to inactivate. 
Under these treatment conditions, the structure of bovine serum albumin protein was well 
preserved.14 
 
In this work we demonstrate inactivation of human immunodeficiency virus (HIV), HAV, 
and murine cytomegalovirus (MCMV) in human plasma using a USP laser operating at a 
wavelength of 425 nm. These pathogens are structurally representative of a broad range 
of viruses including enveloped RNA virus (HIV), non-enveloped RNA virus (HAV), and 
enveloped DNA virus (MCMV). MCMV serves as a surrogate for human herpesviruses 
including HCMV. We used MCMV for this study because it is not infectious to humans, 
allowing us to conduct more detailed studies in a less restrictive environment. MCMV is 
also readily available in our lab and straightforward to analyze on the bench; more 
importantly, as an enveloped DNA virus, MCMV serves structurally as a model for 
clinically relevant enveloped DNA viruses which include Hepatitis B virus, HCMV, and 
poxviruses. The USP laser technology has been shown to inactivate viruses through 
mechanical means; in other words, inactivation by the USP laser is most dependent on 
the structure of a virus.  
 
Furthermore, we assess the function of coagulation factors in treated plasma versus 
untreated plasma after USP laser irradiation.  
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MATERIALS AND METHODS 
 
FEMTOSECOND LASER IRRADIATION 
The excitation source employed in this work was a diode-pumped continuous wave 
mode-locked Ti-sapphire laser (Trestles-100, Del Mar Photonics, USA). The laser 
produced a continuous train of 60 fs pulses at a repetition rate of 80 MHz. The output of 
the second harmonic generation system of the Ti-sapphire laser was used to irradiate the 
sample. The excitation laser was chosen to operate at a wavelength of λ = 425 nm and 
with an average power of approximately 120 mW. This laser wavelength was chosen 
because we have recently demonstrated that it was capable of efficiently inactivating 
enveloped/non-enveloped, DNA/RNA viruses including HIV, MCMV, murine norovirus, 
encephalomyocarditis virus, and human papillomavirus.11 It has a pulse width of full-
width at half maximum = 100 fs. A lens was used to focus the laser beam into a spot 
within the sample volume. Samples were laser-irradiated for 90 min. A magnetic stirring 
device was used to facilitate exposure of the sample to the laser beam. Irradiation was 
carried out at 22°C and with the single laser beam excitation. After laser irradiation, 
samples were immediately stored at -80°C. 
 
VIRUSES AND INFECTIVITY ASSAYS 
HIV inactivation. HIV stock was propagated in MT-4 cells following transfection of 
HeLa cells with pNL4-3 plasmid (both MT-4 cells an pNL4-3 were kind gifts of Dr. 
Kuan-Teh Jeang). Approximately 4x106 reverse transcriptase (RT) units of NL4-3 stock 
was added to pooled normal plasma (George King Biomedical, Inc., Overland Park, KS). 
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The infected plasma was placed into each of 6 glass vials for transport to the laser lab. 
Each of the 3 vials containing a stir bar was laser-irradiated as described above. During 
the treatment time, a vial serving as a room temperature control was placed in a beaker in 
the same room. During each treatment time, 4 of the 6 vials remained on ice. When each 
of 3 vials had been irradiated, all 6 vials were transported back to the HIV lab, where 
they were stored at -80°C until used in a Multinuclear Activation Galactosidase Indicator 
(MAGI) assay. For the MAGI assay, the MAGI cells (U373-MAGI-CXCR4 CEM, 
catalog #3596, contributed by Dr. Michael Emerman) were obtained through the NIH 
AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH, 
Bethesda, USA. The standard MAGI assay protocol was followed. Briefly, plasma/virus 
mixture was added to MAGI cells, incubated for 48 h, fixed with 4% paraformaldehyde 
for 2 h, and X-gal (Teknova, USA, Cat # X1205) staining was visualized. Three 
irradiated samples, three room temperature control samples, and the original virus stock 
were used in the assay. The final dilution factor for treated samples and controls was 1:2 
compared to the original virus stock dilution used in the assay.  
 
HAV inactivation. HAV stock was obtained from the American Type Culture Collection 
(Manassas, VA) as VR1402, a cell culture-adapted cytopathic clone of strain HM-175 
that was originally designated as HM-175/18f. The virus was propagated on fetal rhesus 
monkey kidney (FRhK-4) cells as previously described.15 The HAV stock was stored at -
70°C in DMEM (Gibco, Grand Island NY) with 10% fetal bovine serum (FBS) (Gibco) 
prior to use. To partially purity HAV, the virus was pelleted at 490,000xg for 6 h, 
followed by resuspension of the HAV in human plasma (George King Biomedical Inc., 
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Overland Park, KS) and filtration through a 0.1 µm filter. Samples of human plasma 
alone or human plasma spiked with HAV were laser-irradiated as described above. 
Plaque assay was performed by making an initial 100-fold dilution followed by 10-fold 
serial dilutions made in Earle’s balanced salt solution (Gibco) and infecting 100-mm 
dishes confluent with FRhK-4 cell and infecting with 2 ml of virus dilution as described 
previously.16 After 2 h, the plates were overlaid with DMEM medium with 5% FBS, and 
1% agarose (Sigma-Aldrich, St. Louis, MO). At 17 days post-inoculation, HAV was 
inactivated by 10% formaldehyde treatment, the agarose overlay was removed, and HAV 
plaques were visualized by crystal violet staining (Fisher Scientific, Kalamazoo, MI). 
 
MCMV inactivation. Murine embryonic fibroblast 10.1 (MEF 10.1) cells17 (a generous 
gift from Dong Yu, Washington University School of Medicine, St Louis, MO) were 
cultured in Dulbecco’s Modified Eagle Medium (DMEM), supplemented with 10% FBS, 
1 mM sodium pyruvate, and nonessential amino acids. GFP-expressing MCMV virus 
(hereafter referred to as ‘‘MCMV’’) was generated as previously described.18 To produce 
viral stocks, MEF 10.1 cells were infected with MCMV at a low multiplicity of infection. 
Cell supernatants were harvested 24 h post-infection after 100% cytopathic effect and 
cleared of cell debris by centrifugation. Extracellular virions were pelleted by 
ultracentrifugation with sorbitol cushion and resuspended in phosphate-buffered saline 
(PBS). Samples of human plasma alone or human plasma spiked with MCMV were laser-
irradiated as described above. Viral titers were determined using a median tissue culture 
infectious dose (TCID50) assay, as previously described.13 Briefly, MEF 10.1 cells were 
seeded into 96-well plates at a density of 1.25x105 cells/ml and incubated overnight. 
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Cells were approximately 80% confluent at the time of infection. Laser-treated or control 
(untreated) viruses were serially diluted and added to cells, which were incubated for 4 
days. Viral titers were determined on day 4 post-infection by scoring each well for GFP-
positive cells using a fluorescent microscope. 
 
COAGULATION FACTOR ASSAYS 
To evaluate the activity of coagulation factors in plasma with or without USP laser 
treatment, we performed standard coagulation factor assays.19 Plasma samples derived 
from the same lot of pooled normal human plasma (George King Biomedical, Inc.) were 
kept untreated or laser-treated as described previously. Factor (F) II, FV, FVII, FVIII, 
FIX, FX, FXI, FXII, and fibrinogen were evaluated in Barnes-Jewish Hospital 
Laboratory, St. Louis, MO. Assays were completed on the IL ACL TOP 700, according 
to the manufacturer’s protocols contained within the package inserts (Instrumentation 
Laboratories Company, Bedford, MA). Plasma levels of FII, FV, FVII, and FX were 
determined using functional assays based on the prothrombin time with human plasma 
immunodepleted of FII, FV, FVII, or FX. Similarly, plasma levels of FVIII, FIX, FXI, 
and FXII were determined using the activated partial thromboplastin time with human 
plasma immunodepleted of FVIII, FIX, FXI, and FXII. Plasma deficient in FII, FV, FVII, 
FVIII, FIX, FX, FXI, or FXII consisted of human plasma that was immunodepleted of the 
individual coagulation factors, and were purchased from Instrumentation Laboratories 
Company. HemosIL RecombiPlasTin 2G and HemosIL SynthASil (Instrumentation 
Laboratories Company) were additional reagents used in the assay. Fibrinogen level was 
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determined by a quantitative assay based on the Clauss method20,21 using Q.F.A. 
Thrombin (Bovine) reagent (Instrumentation Laboratories Company). 
 
PROTEIN GEL ELECTROPHORESIS 
To evaluate protein aggregation of samples with or without USP laser treatment, we 
employed gel electrophoresis analysis. For SDS-PAGE, control (untreated) or laser-
treated samples containing equivalent quantities of plasma were boiled in loading buffer 
(dH2O (47.5%), 0.5 M Tris pH 6.8 (12.5%), glycerol (10%), SDS (20%), b-
mercaptoethanol (5%), and bromophenol blue (5%)) under reducing conditions, and 
separated on a Mini-Protean TGX 10% precast polyacrylamide gel (Bio-Rad, Hercules, 
CA). For native PAGE, control (untreated) or laser-treated samples containing equivalent 
quantities of plasma were separated on the 10% gel under non-denaturing conditions. 
Protein bands were visualized with Coomassie blue staining (LabSafe Gel Blue, G-
Biosciences). 
 
FIBRINOGEN PROTEIN PREPARATION 
Purified human fibrinogen was obtained from Haemtech Technologies, Inc (Essex 
Junction, VT). For protein structure characterization measurements, fibrinogen solutions 
(2.5 mg/ml) were prepared by dissolving pure, lyophilized peptide in PBS buffer which 
was filtered with a 0.02 mm Whatman Anotop25 filter. The actual concentration was 
checked by measuring the absorption of the sample with a Cary50 UV-Vis 
spectrophotometer (Agilent, Inc., Santa Clara, CA), using an extinction coefficient of 
fibrinogen at 280 nm of 5.12x105 M-1 cm-1. Dynamic light scattering (DLS), circular 
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dichroism (CD) and absorbance measurements were carried out immediately before and 
after irradiation of the sample. 
 
DYNAMIC LIGHT SCATTERING MEASUREMENTS 
To determine the effect of USP laser treatment on the aggregation of fibrinogen protein, 
we employed dynamic light scattering analysis. Before and after irradiation, fibrinogen 
samples were centrifuged at 12,000xg for 15 min to clear them from dust, and 5 ml 
aliquots were taken to measure the DLS signal of the sample. Autocorrelation functions 
of the scattered intensity at 90° scattering angle were collected at 25°C with a 5 sec 
acquisition time, using a Wyatt Technology DynaPro NanoStar with a 658 nm, 120 mW 
GaAs linearly polarized laser. Measurements of fibrinogen were done in a 1 ml 
MicroCuvette (Wyatt Technology Corp., Santa Barbara, CA), previously calibrated with 
clear water. Data were analyzed using Wyatt Technology Dynamics 7 software, using a 
regularization fit method to determine hydrodynamic radii of fibrinogen from the 
autocorrelation functions. 
 
CIRCULAR DICHROISM MEASUREMENTS 
To examine laser-induced alterations in the secondary structure of fibrinogen protein, 
circular dichroism measurements were made. Immediately before and after irradiation, an 
aliquot of the fibrinogen sample was diluted (1:20 for the 2.5 mg/ml sample and 1:10 for 
1.5 mg/ml and 0.6 mg/ml samples) and transferred to a 1 mm quartz cuvette (Starna Cells, 
Atascadero, CA, USA) and circular dichroism spectra were measured at room 
temperature using J-710 spectropolarimeter (Jasco Instruments, Easton, MD). Far UV 
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spectra from 200 nm to 250 nm were obtained by averaging over eight scans, with a 1 nm 
bandwidth, 0.5 nm pitch and 50 nm/min scan speed, and then buffer subtracted. 
Fibrinogen concentration was estimated from the absorption spectra of undiluted samples, 
measured before and after laser irradiation. These values were used to convert CD signals 
to mean residue ellipticity (MRE). We note that a slight decrease in the signal amplitude 
was observed each time the samples were transferred from one container to another. This 
was consistent with the expected loss of protein due to adsorption of fibrinogen to the 
surface of containers.22 
 
STATISTICS 
Quantitative experiments were performed in triplicate. Differences between mean titers 
of control and laser-treated virus were analyzed by Student’s t-test using Graphpad Prism 
and Microsoft Excel software. p<0.05 was used as a threshold for statistical significance. 
 
RESULTS  
 
USP laser treatment inactivates viruses in human plasma 
For this study, we chose HIV and HAV as medically significant enveloped and non-
enveloped RNA viruses, respectively, and we chose MCMV as a representative 
enveloped DNA virus whose results could be extrapolated to relevant human pathogens 
such as cytomegalovirus and hepatitis B virus. To demonstrate that the USP laser 
treatment can inactivate viruses in plasma, aliquots of HIV, HAV, or MCMV were spiked 
into human plasma and treated with the laser. USP laser treatment of virus-spiked plasma 
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samples resulted in approximately 2-log, 1-log, and 3-log reductions in HIV, HAV, and 
MCMV titers, respectively (Figure 1A–C). The reduction in HAV titers after USP laser 
treatment exceeds that achieved by the currently licensed SD and amotosalen techniques.6 
It is anticipated that further optimization of laser parameters such as wavelength (i.e., 
operating at wavelengths where absorption by bilirubin/hemoglobin are minimal) would 
yield greater inactivation of viruses. These data indicate that USP laser treatment can 
achieve clinically meaningful reduction of viruses in human plasma. 
 
 
 
 
Figure 1. Inactivation of viruses in plasma using a USP laser. Human 
plasma containing HIV (A), HAV (B), or MCMV (C) were treated with 
the USP laser. For the HIV-spiked plasma, viral titer was assessed by 
plaque assay in MAGI cells. For the HAV-spiked plasma, viral titer was 
assessed by plaque assay in fetal rhesus monkey kidney cells. For the 
MCMV-spiked plasma, viral titer was assessed by TCID50 assay in murine 
embryonic fibroblast cells. Results are representative of triplicate 
experiments and are shown as means ± SEM. 
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The function of human plasma proteins is preserved after USP laser treatment 
To determine the functional integrity of human plasma after USP laser treatment, we 
laser-treated human plasma alone using the same conditions used to inactivate the viruses. 
After treatment, samples were subjected to standard coagulation assays. Human 
coagulation factors in laser-treated plasma showed preservation of activity comparable to 
that achieved with other clinically tested PR methods.6 The percent retention of 
individual coagulation factors after laser treatment relative to control is shown in Table 1. 
With the exception of Factor VII, the activities of all the plasma proteins were near or 
within the normal reference range. Relative to non-irradiated sample, Factors II, V, VII, 
IX, and X showed ≥90% retention. Factor XII and fibrinogen showed ≥70% retention. 
Factors VIII and XI were the most sensitive and showed 68% and 54% retention, 
respectively. Although Factor II activity was increased by 20% relative to control (p= 
0.04), the value still fell within the normal reference range, and similar small increases in 
the activity of certain factors after treatment using current PR methods have been 
reported, potentially due to the intrinsic variation in the assay.2 As an example, riboflavin 
treatment was previously shown to increase the measured activity of Factor XIII to 113% 
the control value.6 Therefore, we did not attribute clinical significance to the observed 
increase in Factor II activity. Interestingly, the USP laser treatment caused a dramatic 
enhancement in the measured activity of Factor VII in plasma (Table 1). This effect could 
either be direct (i.e., laser-induced structural changes in Factor VII protein) or indirect 
(i.e., laser-induced damage to factor(s) that inhibit Factor VII activity). We believe that 
the latter scenario is more likely, since it is difficult to envision how USP laser treatment 
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could directly increase the activity of Factor VII protein by altering its native structure. 
Therefore, a plausible explanation is that the USP laser treatment may cause damage to 
Factor VII inhibitor(s) that are present in human plasma (such as tissue factor pathway 
inhibitor, TFPI), which leads to an apparent “enhancement” in measured Factor VII 
activity. It is expected that further optimization of laser parameters such as wavelength 
(i.e., operating at wavelengths where absorption by bilirubin and/or hemoglobin are 
minimal) would yield greater preservation of plasma proteins. These data demonstrate 
that USP laser irradiation retains coagulation factor activities in an acceptable range for 
clinical translation. 
 
 
Table 1. Retention of coagulation factor activity for USP laser-treated 
plasma. The function of individual coagulation factors in control 
(untreated) or USP laser-treated plasma was assessed using standard 
coagulation assays. 
 
 
USP laser treatment does not induce detergent-resistant aggregation in human plasma 
proteins 
To determine the effects of laser treatment on human plasma proteins, we analyzed 
control (untreated) and laser-treated plasma by SDS-PAGE (Figure 2A, left panel). Both 
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control and laser-treated plasma contained some intrinsic level of detergent-resistant 
aggregates as evidenced by the presence of low-mobility protein complexes that are 
unable to migrate through the gel. However, USP laser treatment of plasma did not cause 
any significant qualitative increase in these aggregates. We were also unable to find 
evidence for any laser-induced increase in detergent-resistant aggregates in plasma by 
native PAGE (Figure 2B). These data suggest that USP laser treatment does not induce 
detergent-resistant aggregation among plasma proteins. 
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Figure 2. SDS-PAGE and native PAGE analysis of control and USP laser-
treated plasma proteins. (A) On the left is shown the SDS-PAGE of 
control and laser-treated plasma; on the right, for comparison, is shown 
the SDS-PAGE of laser-treated MCMV virus adapted from Tsen et al [13] 
(reprinted with permission from the Society of Photo-Optical 
Instrumentation Engineers). Control (untreated) or USP laser-treated 
plasma were boiled in reducing buffer and separated on a 10% gel. 
Proteins were visualized by Coomassie blue stain. The solid arrow 
indicates the location of low mobility detergent-resistant aggregates; the 
dotted arrow indicates missing band(s) corresponding to aggregated 
proteins. (B) Native PAGE of control and laser-treated plasma. Control 
(untreated) or USP laser-treated plasma were separated on a 10% gel. 
Proteins were visualized by Coomassie blue stain. Arrows indicate 
location of low mobility detergent-resistant aggregates. 
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Figure 3. Structural analysis of control and laser-treated fibrinogen protein. 
Control (untreated) or laser-treated fibrinogen protein was analyzed by 
circular dichroism. The red line indicates the CD spectrum of control 
fibrinogen, while the dotted black line indicates laser treated fibrinogen. 
The spectra (in Mean Residue Ellipticity, rescaled for concentration) show 
virtually complete overlap. 
 
 
 
The secondary structure and aggregation state of purified human fibrinogen are 
unaltered after USP laser treatment 
As shown in Table 1, the function of some coagulation factors was reduced after laser 
treatment. In particular, the function of fibrinogen, which is the coagulation factor that 
occurs at the highest concentration in plasma (~2–4 mg/ml) among the factors tested, was 
reduced to 73% of control. To determine if direct, laser-induced change in protein 
structure and/or aggregation state of the protein itself was responsible for this reduction 
in function, we analyzed the structure and aggregation state of purified human fibrinogen 
  166 
protein at physiological concentration (2.5 mg/ml) after USP laser treatment using 
circular dichroism and dynamic light scattering analysis, respectively. 
 
We found no evidence for laser-induced alterations in the secondary structure of 
fibrinogen by circular dichroism measurements (Figure 3). Furthermore, we did not 
observe any significant laser-induced aggregation of fibrinogen protein by dynamic light 
scattering, as evidenced by near-identical proportions of monomer in both control and 
laser-treated groups (Table 2). We note that these values represent the percentage of 
scattered intensity from monomers (i.e. species with hydrodynamic radius of 12 nm). In 
both the controls and the irradiated samples, the remaining 40% of intensity came from a 
much larger species, with a hydrodynamic radius around 100 nm. Because large 
aggregates scatter much more than monomers, these values indicate that roughly 90% of 
the protein mass was monomeric (assuming that the aggregates are spherical). Similar 
results were obtained with fibrinogen at lower concentrations (1.5 mg/ml and 0.6 mg/ml). 
These findings indicate that USP laser treatment does not directly cause alterations in the 
secondary structure or aggregation state of purified fibrinogen protein itself when the 
protein is treated at physiological or sub-physiological concentrations. 
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Table 2. Aggregation state of control and laser-treated fibrinogen protein. 
Control (untreated) or laser-treated purified fibrinogen protein was 
analyzed for aggregation state by dynamic light scattering. Values 
corresponding to the percentage of scattered intensity from Fibrinogen 
monomers are shown. 
 
 
DISCUSSION 
 
In this report we demonstrate inactivation of representative viruses in plasma using a 
visible USP laser, with preservation of plasma proteins. Although we achieved significant 
reductions in virus, we note that the laser inactivation efficiency for viruses in plasma is 
decreased relative to that for viruses in phosphate buffered saline (PBS).13,23 This is likely 
due to the reduced penetration of light through plasma, which is less transparent than 
PBS. This can be remedied by designing a laser treatment chamber that is sufficiently 
thin (<1 mm depth) to maximize light transmission. For example, in a continuous-flow 
treatment scenario (for example using a syringe pump), a tube or capillary with a small 
depth would ensure more complete exposure of the sample to the laser light. In future 
studies, we estimate that the use of more powerful commercially available lasers would 
enable focused spot sizes on the order of millimeters. Coupled with continuous flow 
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systems, this could provide a plasma treatment efficiency on the order of ~100 ml per 
minute which would bring the technology closer to clinical plausibility.  
 
After USP laser treatment, most coagulation factor activities were retained in the range of 
70–100% control. Typically, in the field of blood transfusion the acceptable retention 
percentage of protein activities for PR methods in human plasma is about 70%.6 For 
example, methylene blue (MB)-treated plasma has been used extensively in the clinic, 
and this method reduces the activity of several proteins to this threshold (fibrinogen, 65%; 
FVIII, 67%).6 Other clinically employed methods such as amotosalen have similar 
damage profiles. The proteins (except Factor XI) in human plasma treated with our USP 
laser technology were retained at around 70% activity or above (Table 1); therefore, it 
should be considered to be meeting this requirement. We believe that this non-invasive 
USP laser technology will have minimal side effects partly because of the nature of the 
inactivation mechanism by the USP laser irradiation, and partly because no chemicals are 
introduced in the treatment process. Therefore, using human plasma treated with the USP 
laser irradiation would be safer compared with other PR methods. Although the level of 
preservation is in the range of other established PR methods, there is potential for 
improvement. Human plasma contains bilirubin, a molecule that absorbs light at the 425 
nm wavelength we used for laser PR.24 This absorption leads to intermolecular energy 
transfers that may negatively affect the structure of bilirubin-associated proteins in 
plasma. Since viruses in PBS alone are efficiently inactivated by USP laser treatment,12-
14,23,25-27
 bilirubin is clearly not required for laser PR. Thus it is possible that by selecting 
a different wavelength where absorption by bilirubin is minimized, the detrimental effects 
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of the USP laser treatment on plasma proteins can be mitigated. For example, use of near-
infrared excitation wavelengths above 700 nm will improve the penetration depth of light 
and minimize absorption of light by plasma proteins for effective pathogen inactivation.  
 
Previous data supported a model whereby the USP laser inactivates enveloped viruses 
such as MCMV by laser-driven excitation of vibrational modes within viral capsids, 
resulting in aggregation of densely-packed tegument and capsid proteins.13,28 The laser 
treatment caused the formation of large, strongly bound aggregates of viral capsid/matrix 
proteins that did not readily dissociate under denaturing or reducing conditions, which we 
term “detergent-resistant aggregates”.13 Figs. 2A and 2B demonstrate that USP laser 
treatment does not induce detergent-resistant aggregates in human plasma. On the other 
hand, our previous gel results on the control and USP laser-treated MCMV in buffered 
solution, which is shown in the right panel of Fig. 2A, indicated that USP laser irradiation 
caused detergent resistant aggregates, leading to the inactivation of MCMV. 
 
Ideally, it is the gel analysis for the MCMV in human plasma that needs to be made. 
However, we have found that the signature signal of MCMV was overwhelmed by the 
tremendously large background contributions from the various components present in the 
human plasma in the gel analysis of the MCMV spiked in human plasma. As a result, the 
analysis is too complicated to be reliably made. Therefore, we chose to analyze the best 
possible experiments next to the ideal one, namely purified MCMV in buffered solution. 
Because the analysis of the gel results on the purified MCMV is not the ideal one, as a 
compromise, we make a reasonable assumption that the effects of USP laser treatment on 
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enveloped viruses such as MCMV are the same in the buffered solution as in the human 
plasma. This assumption is reasonable because it is supported by our observations that 
MCMV is efficiently inactivated by the USP laser irradiation both in the buffered 
solution and in human plasma. Under this assumption, it can be shown that the protein 
aggregation induced by the USP laser irradiation is a plausible mechanism for our 
experimental   observations that the USP laser efficiently inactivates viruses while 
retaining protein activities in the human plasma. The protein aggregation induced by the 
USP laser irradiation has been demonstrated to be density-dependent;13 namely, the more 
closely the proteins are packed, the larger the probability of protein aggregation. Because 
the protein density is significantly higher within the MCMV virion than in human plasma, 
it is expected that protein aggregation by the USP laser irradiation would be much more 
probable within the MCMV than in the human plasma, leading to the efficient 
inactivation of MCMV but retention of the majority of coagulation factor activities in 
human plasma. 
 
We also note that that ideally, it is the fibrinogen within human plasma that needs to be 
analyzed. However, we have found that the CD and DLS analyses for fibrinogen in 
human plasma are too complicated to be reliably made due to the presence of background 
contributions from other components present in the human plasma. Therefore, we chose 
to analyze the best possible experiments next to the ideal one, namely the CD and DLS of 
purified fibrinogen. Because the CD and DLS analysis of purified fibrinogen is not the 
ideal one, as a compromise, we choose not to make a definitive conclusion based on the 
CD and DLS results on purified fibrinogen. Instead, we conclude that the CD and DLS 
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results on purified fibrinogen provide a possible clue to explain why the USP laser 
irradiation preserves the majority (73%) of the fibrinogen activity in human plasma. 
 
We were unable to correlate the observed reduction in plasma protein function with any 
changes in the secondary structure or aggregation state of the proteins. There are two 
potential explanations for this observation. Firstly, the USP laser may cause only minimal 
structural damage to these proteins at a level undetectable by circular dichroism, dynamic 
light scattering, and SDS-PAGE. In this case, more sensitive methods such as nuclear 
magnetic resonance may be required to elucidate these changes. Alternatively, the 
function of plasma proteins might be indirectly inhibited by laser-induced damage to 
other factors in plasma that promote the coagulation activity of these proteins. Indeed, the 
absorption of laser light by other molecule(s) present in plasma, such as bilirubin, might 
lead to energy transfer from these molecule(s) to closely bound/closely associated 
proteins. Studies on the effect of bilirubin on plasma protein preservation after USP laser 
treatment are currently underway.  
 
Visible USP laser treatment provides important advantages in the field of PR. The USP 
laser technology does not involve introducing potentially toxic or carcinogenic chemicals, 
and thus avoids possible side effects from such additives. Unlike the SD and amotosalen 
methods, which have seen significant clinical use in Europe, USP laser treatment can 
inactivate non-enveloped viruses. In addition, USP lasers are non-ionizing and do not 
disrupt covalent bonds, thereby reducing the potential to generate immunogenic 
neoantigens in blood products. Furthermore, USP lasers are environmentally friendly, 
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circumventing the need to incorporate undesirable compounds such as mercury which is 
used in UV lamps. 
 
Such qualities make USP lasers a promising potential method for sterilization not only of 
blood products, but of pharmaceuticals, biologicals, and cell culture as well. As described 
above, the ISRS inactivation mechanism of USP lasers is very likely to leave small 
molecule pharmaceuticals and soluble recombinant proteins structurally undamaged. In 
addition, we have previously shown that a therapeutic window exists for which viruses 
and bacteria can be inactivated without causing death in human cells.12 Studies are 
currently ongoing to conclusively demonstrate these applications. 
 
CONCLUSION  
 
We have performed PR experiments on three representative viruses in human plasma by 
using a visible USP laser. Our experimental results demonstrate that it is feasible to use 
this novel USP laser technology to inactivate viruses while retaining the function of 
coagulation factors in human plasma at a clinically acceptable level. This is the first 
proof-of-concept study of PR in human plasma using USP lasers. This chemical-free USP 
laser technology has potential advantages over current PR techniques. 
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